Apyx Medical Corporation Stock price
Is Apyx Medical Corporation a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 9,085 stocks worldwide.
StocksGuide Premium
StocksGuide Unlimited
Key metrics
📘 Market Capitalization
📈 What is it?
Market capitalization shows how much a company is currently worth on the stock market.
🧮 How is it calculated?
🏛️ Why is it important?
It helps classify companies by size (Large, Mid, Small Cap) and indicates their market presence and relative stability.
🧮 Calculation
🎯 What does this mean for investors?
- Large-cap companies tend to be more stable, often pay dividends, but may grow more slowly.
- Smaller firms may offer higher growth potential but come with more volatility.
- Market capitalization is a useful indicator of company size — but not a measure of whether a stock is undervalued or overvalued.
📘 Enterprise Value (EV)
📈 What is it?
Enterprise Value represents the total cost to acquire a company — including its debt and excluding its cash reserves.
🧮 How is it calculated?
(= Market Cap + Net Debt)
🏛️ Why is it important?
EV gives a more complete picture of a company's value than market cap alone and is used in key valuation ratios like EV/FCF or EV/Sales.
🧮 Calculation
🎯 What does this mean for investors?
- Enterprise Value shows the true cost of buying a company, including all financial obligations.
- It is more accurate than just looking at market cap, especially when comparing companies with different levels of debt or cash.
- Professional investors prefer EV-based multiples because they better reflect the company’s full financial footprint.
📘 Net Debt
📈 What is it?
Net Debt shows how much debt remains after subtracting a company’s available cash reserves.
🧮 How is it calculated?
🏛️ Why is it important?
It indicates how dependent a company is on borrowed money and how easily it can service its debt in the short term.
🧮 Calculation
🎯 What does this mean for investors?
- Low or negative net debt signals financial strength and flexibility.
- Companies with strong cash positions are better positioned in crises.
- High net debt increases financial risk — especially in environments with rising interest rates or economic downturns.
📘 Cash
📈 What is it?
Cash represents all liquid assets a company can access immediately — including cash, bank deposits, and short-term investments.
🧮 How is it calculated?
🏛️ Why is it important?
It reflects a company’s financial flexibility and resilience — enabling investments, buybacks, or buffer in downturns.
🧮 Calculation
🎯 What does this mean for investors?
- A strong cash position means greater room for maneuver and crisis resistance.
- Cash-rich companies can invest, pay down debt, or repurchase shares.
- But excess idle cash might indicate a lack of growth opportunities.
📘 Shares Outstanding
📈 What is it?
Shares outstanding represent the total number of a company’s shares currently held by investors — excluding treasury stock.
🧮 How is it calculated?
🏛️ Why is it important?
It’s the basis for key metrics like Earnings Per Share (EPS), Market Capitalization, or the Price/Earnings ratio (P/E).
🧮 Calculation
🎯 What does this mean for investors?
- Fewer shares in circulation typically increase earnings per share — making each share more valuable.
- Share buybacks reduce the number of shares and boost per-share metrics.
- Issuing new shares does the opposite — diluting shareholder value and lowering per-share figures.
📘 Price-to-Earnings Ratio (P/E)
📈 What is it?
The P/E ratio shows how many times a company's earnings per share are reflected in its current share price — in other words, how "expensive" the stock appears relative to its profits.
🧮 How is it calculated?
🏛️ Why is it important?
The P/E ratio is one of the most widely used valuation metrics. It helps investors assess whether a stock appears cheap or expensive compared to its earnings power.
🧮 Calculation
📊 P/E (TTM) = Based on earnings from the last 12 months (Trailing Twelve Months):🎯 What does this mean for investors?
- A low P/E may indicate undervaluation — or signal underlying issues.
- A high P/E may reflect strong growth expectations — or an overvalued stock.
📘 Price-to-Sales Ratio (P/S)
📈 What is it?
The P/S ratio shows how much investors are paying for $1 of the company’s revenue – regardless of profitability.
🧮 How is it calculated?
🏛️ Why is it important?
P/S is especially useful for evaluating growth companies or businesses not yet profitable. It reflects how the market values the company’s sales.
🧮 Calculation
Market Cap = $104.89m | Revenue (TTM) = $58.42m
Market Cap = $104.89m | Estimated Revenue = $60.79m
🎯 What does this mean for investors?
- A low P/S may indicate undervaluation — or low profitability.
- A high P/S can reflect strong growth expectations — or excessive optimism.
- Especially helpful when evaluating companies where profits are low, volatile, or negative.
📘 Enterprise Value to Sales (EV/Sales)
📈 What is it?
EV/Sales shows how much investors are paying for $1 of revenue — considering not just equity, but also debt and cash. It’s the capital structure–adjusted version of the P/S ratio.
🧮 How is it calculated?
🏛️ Why is it important?
It’s ideal for comparing companies with different levels of debt. It reflects a company's true cost relative to its revenue.
🧮 Calculation
Enterprise Value = $112.62m | Revenue (TTM) = $58.42m
Enterprise Value = $112.62m | Forward Revenue = $60.79m
🎯 What does this mean for investors?
- EV/Sales allows for capital structure–neutral company comparisons.
- A lower ratio may indicate undervaluation; a higher one may signal strong growth expectations or overvaluation.
- Especially helpful when evaluating high-growth companies with low or negative earnings.
📘 Enterprise Value to Free Cash Flow (EV/FCF) | ex SBC
📈 What is it?
EV/FCF compares a company’s enterprise value with its free cash flow. The metric therefore shows the multiple of current free cash flow at which a company is valued. EV/FCF ex SBC additionally accounts for stock-based compensation (SBC). While SBC does not represent a direct cash outflow, issuing shares as compensation can dilute existing shareholders. Therefore, SBC is deducted from free cash flow in this adjusted version.
🧮 How is it calculated?
EV/FCF ex SBC = Enterprise Value ÷ (Free Cash Flow (TTM) − SBC)
🏛️ Why is it important?
EV/FCF provides a valuation based on free cash flow and therefore complements earnings-based valuation metrics such as the P/E ratio. The ex SBC version additionally accounts for the economic impact of stock-based compensation and provides a more conservative view from a shareholder perspective.
🧮 Calculation
🎯 What does this mean for investors?
- A low EV/FCF means that enterprise value is low relative to current free cash flow. The reasons should always be considered in the context of the company and its industry.
- A high EV/FCF means that enterprise value is high relative to current free cash flow. This can, for example, reflect high growth expectations or temporarily weak cash generation.
- When SBC is positive and adjusted free cash flow remains positive, EV/FCF ex SBC is generally higher than the standard EV/FCF.
- The metric is particularly useful for companies with relatively stable and predictable cash flows.
- If free cash flow is negative or very low, EV/FCF has limited usefulness and should not be interpreted like a standard valuation multiple.
📘 Price-to-Book Ratio (P/B)
📈 What is it?
The P/B ratio compares a company’s market value to its book value — showing how much investors are paying for each dollar of net assets.
🧮 How is it calculated?
🏛️ Why is it important?
P/B is commonly used for asset-heavy industries like banks or industrials. It helps assess whether a stock is trading above or below its net asset value.
🧮 Calculation
🎯 What does this mean for investors?
- A P/B below 1 may signal undervaluation — or weak profitability.
- A P/B above 1 implies the market expects future value creation (e.g., brand, IP, growth).
- Best used for companies with tangible assets and strong balance sheets.
📘 Equity Ratio
📈 What is it?
The equity ratio indicates what portion of a company’s total assets is financed by shareholders’ equity – in other words, how much it relies on its own capital.
🧮 How is it calculated?
🏛️ Why is it important?
A high equity ratio reflects financial strength and stability, especially during downturns. It’s a key indicator of a company’s solvency and long-term risk profile.
🧮 Calculation
🎯 What does this mean for investors?
- Companies with high equity ratios are generally more resilient and less dependent on external debt.
- Low equity ratios can signal higher risk or aggressive financial strategies.
- Important: Always assess the equity ratio in combination with the return on equity (ROE). This shows not just how stable the company is – but also how efficiently it uses shareholder capital.
📘 Return on Equity (ROE)
📈 What is it?
Return on equity (ROE) shows how efficiently a company uses its shareholders’ equity to generate profit. In other words: how much net income is earned per dollar of equity.
🧮 How is it calculated?
🏛️ Why is it important?
ROE is a core profitability metric. It helps investors understand whether a company delivers attractive returns on the capital provided by its shareholders.
🧮 Calculation
🎯 What does this mean for investors?
- A high ROE indicates that the company is using its capital efficiently and profitably.
- It’s especially meaningful for capital-intensive businesses or firms with high equity bases.
- Important: A very high ROE can also result from high debt levels – always interpret it alongside the equity ratio to assess financial health.
📘 Return on Capital Employed (ROCE)
📈 What is it?
ROCE measures how efficiently a company generates profits from its total capital – including both equity and interest-bearing debt.
🧮 How is it calculated?
It evaluates the return on all capital employed, regardless of how it’s financed.
🏛️ Why is it important?
ROCE is ideal for comparing companies with different financing structures. It shows how well management uses capital to create value for both shareholders and creditors.
🧮 Calculation
🎯 What does this mean for investors?
- A high ROCE means the company uses its capital efficiently – regardless of whether it's funded by debt or equity.
- The higher the ROCE compared to peers, the more value the company creates with its invested capital.
- Especially relevant for capital-intensive sectors like industrials, energy, or infrastructure.
📘 Return on Invested Capital (ROIC)
📈 What is it?
ROIC measures how efficiently a company generates returns from the capital invested in its core operations – regardless of whether the capital comes from equity or debt.
🧮 How is it calculated?
- NOPAT = Net Operating Profit After Taxes
- Invested Capital = Operating assets minus non-interest-bearing liabilities
🏛️ Why is it important?
ROIC is one of the most accurate indicators of capital efficiency. Unlike return on equity, it is not distorted by leverage and shows how much value is created for all capital providers.
🧮 Calculation
🎯 What does this mean for investors?
- A high ROIC shows how effectively a company uses the capital that is truly invested in its core operations.
- Unlike ROCE, ROIC focuses only on the capital that is actively used to run the business – and that requires a return (i.e. interest-bearing).
- Especially useful when comparing companies with large amounts of excess cash or non-interest-bearing liabilities – giving a more realistic picture of capital efficiency.
📘 Leverage Ratio (Debt-to-Equity)
📈 What is it?
The leverage ratio indicates how much a company relies on interest-bearing debt (such as loans and bonds) relative to its shareholders’ equity.
🧮 How is it calculated?
🏛️ Why is it important?
This ratio helps assess a company’s financial structure and risk profile. High leverage can enhance returns – but also increases exposure to interest rate changes and financial stress.
🧮 Calculation
🎯 What does this mean for investors?
- A low leverage ratio signals financial strength and independence.
- A higher ratio can improve returns in good times but increases risk during downturns or rising interest rate periods.
- 👉 Always interpret in the context of industry, capital intensity, and interest rate environment.
📘 SBC | in % Revenue
📈 What is it?
SBC (Stock-Based Compensation) refers to equity-based compensation granted by a company to its employees and executives. The percentage shows SBC relative to revenue.
🧮 How is it calculated?
SBC as % of Revenue = (SBC ÷ Revenue) × 100
🏛️ Why is it important?
Stock-based compensation is a real cost factor for shareholders. It can increase the number of shares outstanding and therefore dilute existing shareholders. The percentage of revenue shows how heavily a company relies on equity-based compensation and how significant this form of compensation is relative to the size of the business.
🧮 Calculation
🎯 What does this mean for investors?
- A lower figure is generally positive: Stock-based compensation is relatively small compared with the company's revenue.
- A high figure can indicate greater reliance on stock-based compensation and a higher potential risk of dilution. However, it is also important to consider whether the company offsets dilution through share buybacks.
- The trend over time should also be considered. A high but declining percentage presents a different picture from a persistently high or increasing percentage.
- A single-digit SBC-to-revenue ratio is not unusual among many growth-oriented and technology companies.
📘 SBC as % of FCF
📈 What is it?
SBC (Stock-Based Compensation) refers to equity-based compensation granted by a company to its employees and executives. The percentage shows SBC relative to free cash flow (FCF).
🧮 How is it calculated?
SBC as % of FCF = (SBC ÷ Free Cash Flow) × 100
🏛️ Why is it important?
Stock-based compensation is a real cost factor for shareholders. It can increase the number of shares outstanding and therefore dilute existing shareholders. The percentage of free cash flow shows how significant SBC is relative to the cash generated by the company. Since SBC is non-cash compensation, it is typically not deducted as a cash outflow when calculating FCF.
🎯 What does this mean for investors?
- A lower value is generally favorable. Stock-based compensation is relatively small compared with the company's cash generation.
- A high value means that SBC represents a significant portion of the company's reported free cash flow, even though SBC itself is non-cash.
- The higher the value, the more significant SBC can be as an economic cost to shareholders, particularly when it results in share dilution.
📘 SBC Growth 1Y
📈 What is it?
SBC Growth 1Y shows how much a company's stock-based compensation has changed compared to the previous year.
🧮 How is it calculated?
🏛️ Why is it important?
SBC Growth shows whether stock-based compensation is becoming more or less significant for shareholders. If SBC increases significantly, it can lead to greater shareholder dilution over time. At the same time, SBC is a non-cash expense that reduces earnings on the income statement but is added back in the cash flow statement.
🧮 Calculation
🎯 What does this mean for investors?
- A high positive value is generally negative, as rising SBC can increase the burden on shareholders, particularly through potential dilution.
- What matters is whether the development of SBC is sustainable over the long term. Some level of SBC is common among many growth and technology companies.
📘 Share Count Growth 1Y
📈 What is it?
Share Count Growth 1Y shows how much the number of shares outstanding has increased or decreased over a one-year period.
🧮 How is it calculated?
🏛️ Why is it important?
The number of shares determines how many shares the company's earnings and assets are distributed across. If the share count decreases, existing shareholders' relative ownership increases. If it increases, existing shareholders are diluted. The metric therefore makes dilution and share buybacks directly visible.
🧮 Calculation
🎯 What does this mean for investors?
- A negative value is generally positive, as the number of shares outstanding is decreasing.
- A positive value indicates dilution of existing shareholders.
- A declining share count is not automatically positive: It also matters at what price the shares are repurchased and how the buybacks are financed.
📘 Shareholder Yield
📈 What is it?
Shareholder Yield measures how much capital a company returns to shareholders through dividends and share buybacks, relative to its market capitalization. It goes beyond dividend yield by also including share buybacks.
🧮 How is it calculated?
🏛️ Why is it important?
Dividend yield only tells part of the story. When a company buys back shares and the share count falls, each existing shareholder owns a larger part of the company. When the share count rises, for example through stock-based compensation or new share issuance, existing shareholders are diluted. Shareholder Yield combines both into one metric.
🧮 Calculation
🎯 What does this mean for investors?
- A higher Shareholder Yield indicates more capital being returned to shareholders.
- A negative value means the company issued more new shares than its dividends and buybacks make up for.
- Share buybacks are most beneficial when shares are repurchased at attractive valuations.
- Investors should also consider whether dividends and buybacks are sustainable over time.
📘 Revenue
📈 What is it?
Revenue shows how much a company earns in total from selling its products and services – the gross income before any costs are deducted.
🧮 How is it calculated?
🏛️ Why is it important?
Revenue is one of the key figures to assess a company’s size, market position, and growth potential.
🧮 Calculation
🎯 What does this mean for investors?
- Growing revenue indicates rising demand and can be an early signal of future earnings growth.
- Comparing actual and expected revenue reveals trends in the market environment and analyst sentiment.
- Note: Strong revenue alone isn’t enough – margins and profitability matter just as much.
📘 EBITDA
📈 What is it?
EBITDA stands for “Earnings Before Interest, Taxes, Depreciation, and Amortization.” It reflects a company’s operating profit before the effects of financing, taxes, and accounting depreciation.
🧮 How is it calculated?
🏛️ Why is it important?
EBITDA is widely used to evaluate a company’s operating performance – especially across capital-intensive sectors or international comparisons.
🧮 Calculation
🎯 What does this mean for investors?
- A high or growing EBITDA indicates strong operational profitability – independent of taxes, interest, or accounting methods.
- It’s especially useful for comparing companies across sectors or geographies.
- Important: EBITDA is not a net income figure – it excludes key costs like depreciation and interest.
📘 EBIT
📈 What is it?
EBIT stands for “Earnings Before Interest and Taxes.” It reflects a company’s operating profit after depreciation, but before interest and tax expenses.
🧮 How is it calculated?
🏛️ Why is it important?
EBIT is a core profitability metric that shows how well the company performs in its main business operations – independent of capital structure and tax environment.
🧮 Calculation
🎯 What does this mean for investors?
- A high EBIT indicates strong profitability from the company’s core business – before financial and tax effects.
- It allows better comparison between companies with different debt levels or tax structures.
- Compared to EBITDA, EBIT already accounts for depreciation and reflects capital intensity more clearly.
📘 Net Income
📈 What is it?
Net income is the company’s total profit – the amount left after all expenses, taxes, interest, and depreciation have been deducted.
🧮 How is it calculated?
🏛️ Why is it important?
Net income is the most comprehensive measure of a company’s profitability – showing how much actual profit remains after all business and financing costs.
🧮 Calculation
🎯 What does this mean for investors?
- Growing net income indicates that the company is managing all of its costs efficiently.
- It directly influences valuation metrics like P/E ratio and the company’s dividend capacity.
- Over time, net income trends reveal how resilient and profitable the business model really is.
📘 Free Cash Flow (FCF) | ex SBC
📈 What is it?
Free cash flow shows how much cash remains after a company has covered its operating and capital expenditures. FCF ex SBC additionally deducts stock-based compensation (SBC) to adjust the cash flow for the effect of non-cash SBC.
🧮 How is it calculated?
Free Cash Flow ex SBC = Operating Cash Flow − SBC − Capital Expenditures (CAPEX)
🏛️ Why is it important?
FCF reflects a company’s actual financial strength – independent of reported accounting earnings. It shows how much flexibility a company has for dividends, share buybacks, or debt reduction. FCF ex SBC also deducts stock-based compensation and shows how much cash generation remains after SBC.
🧮 Calculation
🎯 What does this mean for investors?
- High free cash flow indicates that a company has strong financial strength – independent of reported earnings.
- It is often a solid basis for sustainable dividends and share buybacks.
- Declining FCF can be a warning sign, even if reported earnings remain stable.
📘 Revenue Growth
📈 What is it?
Revenue growth shows how much a company’s sales have changed compared to the previous year – both on a trailing basis (TTM) and based on forward projections.
🧮 How is it calculated?
Forward = (Expected revenue ÷ Revenue in prior year − 1) × 100
Forward growth is based on analyst estimates for the current fiscal year.
🏛️ Why is it important?
Rising revenue signals growing demand, business expansion, and market share gains – especially important for growth-oriented companies.
🧮 Calculation
🎯 What does this mean for investors?
- Growth is the engine of long-term value creation – especially in tech and growth sectors.
- What matters is not just current growth, but its sustainability.
- Forward projections reflect whether analysts expect continued momentum – or a slowdown.
📘 EBITDA Growth
📈 What is it?
EBITDA growth shows how much a company’s operating profit (before interest, taxes, depreciation, and amortization) has increased or decreased compared to the previous year.
🧮 How is it calculated?
Forward = (Expected EBITDA ÷ EBITDA from prior year − 1) × 100
The forward estimate is based on analyst projections for the current fiscal year.
🏛️ Why is it important?
Growing EBITDA indicates improving operational profitability – regardless of financing or accounting effects.
🧮 Calculation
🎯 What does this mean for investors?
- Strong EBITDA growth signals operational efficiency and scalability – especially during growth phases.
- EBITDA growth can be an early indicator of margin and earnings expansion – but should be assessed alongside revenue and EBIT.
📘 EBIT Growth
📈 What is it?
EBIT growth shows how much a company’s operating profit (after depreciation, but before interest and taxes) has increased compared to the previous year.
🧮 How is it calculated?
Forward = (Expected EBIT ÷ EBIT from prior year − 1) × 100
The forward estimate is based on analyst projections for the current fiscal year.
🏛️ Why is it important?
EBIT growth is a direct indicator of a company’s business performance – taking into account capital intensity through depreciation.
🧮 Calculation
🎯 What does this mean for investors?
- Rising EBIT signals improving operating profitability – even after accounting for depreciation.
- It’s especially important for evaluating companies with significant capital expenditures.
- Combined with revenue and EBITDA growth, EBIT growth provides a well-rounded view of operational progress.
📘 Net Income Growth
📈 What is it?
Net income growth shows how much a company’s bottom-line profit has increased or decreased compared to the previous year – both on a trailing basis (TTM) and based on analyst projections.
🧮 How is it calculated?
Forward = (Expected net income ÷ Net income from prior year − 1) × 100
The forward estimate reflects analysts’ expectations for the current fiscal year.
🏛️ Why is it important?
Net income is the ultimate measure of profitability. Growing net income signals stronger efficiency, cost control, and sustainable earnings power.
🧮 Calculation
🎯 What does this mean for investors?
- Stronger net income boosts valuation, dividend potential, and investor confidence.
- If profits stall while revenue grows, it may signal margin pressure.
📘 Free Cash Flow Growth
📈 What is it?
Free cash flow (FCF) growth shows how a company’s available cash – after covering operating expenses and capital expenditures – has changed compared to the previous year.
🧮 How is it calculated?
🏛️ Why is it important?
Free cash flow reflects real financial strength. Growing FCF indicates more flexibility for dividends, share buybacks, and reinvestment.
🧮 Calculation
🎯 What does this mean for investors?
- Declining FCF may point to rising investments, increasing costs, or weaker operating performance.
- Especially for dividend investors, FCF growth is critical – since dividends are paid from actual available cash.
- A negative trend isn't always bad, but it deserves closer attention.
📘 Gross Margin
📈 What is it?
Gross margin shows how much of a company’s revenue remains after deducting the direct costs of goods sold (like materials and production). It represents the company’s “raw profit” before fixed costs, taxes, and interest.
🧮 How is it calculated?
Or simply: Gross Margin = Gross Profit ÷ Revenue × 100
🏛️ Why is it important?
Gross margin indicates how efficiently a company can produce or procure what it sells. It is a key measure of product-level profitability and pricing power.
🧮 Calculation
🎯 What does this mean for investors?
- A high gross margin suggests strong pricing power and efficient production.
- Falling margins may signal rising input costs or competitive pressure.
- Compared to peers, gross margin offers insights into the quality of a business model.
📘 EBITDA Margin
📈 What is it?
The EBITDA margin shows how much of a company’s revenue remains as operating profit before interest, taxes, depreciation, and amortization.It reflects operating efficiency without being distorted by financing or accounting factors.
🧮 How is it calculated?
🏛️ Why is it important?
The EBITDA margin reveals how much operating income a company generates per dollar of revenue – independent of capital structure and tax effects.
🧮 Calculation
🎯 What does this mean for investors?
- A high EBITDA margin reflects strong core profitability – before accounting distortions.
- It allows for effective comparisons across companies and sectors.
- A stable or growing margin signals efficient cost control and business scalability.
📘 EBIT Margin
📈 What is it?
The EBIT margin shows what percentage of revenue remains as operating profit after depreciation but before interest and taxes.
🧮 How is it calculated?
🏛️ Why is it important?
The EBIT margin reflects a company’s core profitability while accounting for capital intensity (e.g. machinery, infrastructure). It’s especially useful for comparing businesses with different levels of depreciation.
🧮 Calculation
🎯 What does this mean for investors?
- A high EBIT margin shows that the company remains efficient even after factoring in depreciation.
- It’s especially relevant for capital-intensive industries.
- Stable or rising EBIT margins over time are a strong indicator of pricing power and business quality.
📘 Net Margin
📈 What is it?
Net margin shows how much of a company’s revenue remains as bottom-line profit after deducting all costs, interest, taxes, and depreciation.
🧮 How is it calculated?
🏛️ Why is it important?
Net margin reflects a company’s overall efficiency – across operations, financing, and taxation. It shows how much actual profit is generated from each dollar of revenue.
🧮 Calculation
🎯 What does this mean for investors?
- A high net margin means the company is not only strong operationally but also manages financing and taxes efficiently.
- Peer comparisons reveal business quality and competitiveness.
- Declining margins despite revenue growth can be a red flag for rising costs or inefficiencies.
📘 Free Cash Flow Margin | ex SBC
📈 What is it?
The Free Cash Flow Margin shows how much free cash flow a company generates relative to its revenue. In simplified terms, free cash flow is calculated as operating cash flow minus capital expenditures. The Free Cash Flow Margin ex SBC additionally accounts for stock-based compensation (SBC). While SBC does not represent a direct cash outflow, issuing shares as compensation can dilute existing shareholders. Therefore, SBC is deducted from free cash flow in this adjusted metric.
🧮 How is it calculated?
Free Cash Flow Margin ex SBC = (Free Cash Flow − SBC) ÷ Revenue × 100
🏛️ Why is it important?
The Free Cash Flow Margin shows how efficiently a company converts its revenue into free cash flow. Strong free cash flow can provide financial flexibility for dividends, share buybacks, debt repayment, or further investments. The ex SBC version additionally accounts for the economic impact of stock-based compensation and therefore provides a more conservative view of cash generation from a shareholder perspective.
🧮 Calculation
🎯 What does this mean for investors?
- A high Free Cash Flow Margin shows that a company converts a high proportion of its revenue into free cash flow.
- This can provide greater financial flexibility for dividends, share buybacks, debt repayment, or investments.
- The Free Cash Flow Margin ex SBC additionally accounts for potential shareholder dilution from stock-based compensation.
- The long-term trend is particularly important. Declining margins can, for example, result from higher investments, changes in working capital, or weaker operating performance.
📘 Earnings per share (EPS)
📈 What is it?
Earnings per Share (EPS) shows how much profit is attributable to a single share – and is one of the most important metrics for evaluating a company's performance.
🧮 How is it calculated?
The diluted share count reflects potential new shares that could be issued through options, convertible bonds, or other rights.
🏛️ Why is it important?
EPS is the basis for many key valuation metrics like P/E ratio, PEG ratio, or payout ratio. It enables comparisons of profitability across companies, regardless of their size.
🧮 Calculation
🎯 What does this mean for investors?
- EPS captures per-share profitability and is especially useful for comparisons over time or with analyst estimates.
- Rising EPS may signal consistent growth or share buybacks.
- Important: Always use diluted EPS for more realistic valuations – especially in companies with stock-based compensation.
📘 Free cash flow per share (FCF per share)
📈 What is it?
Free Cash Flow per Share shows how much free cash flow a company generates per outstanding share – after investments, but before dividends or debt repayments.
🧮 How is it calculated?
Free cash flow is calculated as operating cash flow minus capital expenditures (CapEx).
🏛️ Why is it important?
FCF per Share reveals how much real cash is available per share – useful for dividends, buybacks, or reducing debt. Unlike net income, free cash flow is harder to manipulate and often seen as a more reliable metric.
🧮 Calculation
🎯 What does this mean for investors?
- High FCF per share signals strong financial flexibility.
- It shows how much capital the company can effectively reinvest or return to shareholders.
- Particularly relevant for dividend payers and capital-efficient businesses.
📘 Short interest
📈 What is it?
Short interest indicates how many shares of a company are currently sold short – that is, borrowed and sold by investors who expect the price to decline.
🧮 How is it calculated?
It reflects the percentage of a company’s shares that are being shorted relative to the total shares available.
🏛️ Why is it important?
Short interest serves as a sentiment indicator: A high value may signal skepticism or bearish expectations – but also increases the potential for a short squeeze if prices rise unexpectedly.
🧮 Calculation
🎯 What does this mean for investors?
- Low short interest usually indicates market confidence in the company.
- High short interest can be a warning sign – or an opportunity if sentiment shifts.
- Especially relevant in volatile markets or ahead of key earnings releases.
📘 Employees
📈 What is it?
The employee count shows how many people a company employs worldwide – offering insights into its size, structure, and business model.
🧮 How is it calculated?
🏛️ Why is it important?
It helps assess operational scale, labor intensity, and cost structure. Combined with revenue and profit, it enables key metrics like revenue per employee or productivity.
🧮 Calculation
🎯 What does this mean for investors?
- A high headcount can signal operational complexity – but also significant growth capacity.
- Revenue per employee is a key indicator of efficiency.
- Especially useful for comparing tech, industrial, or service-heavy companies.
📘 Revenue per employee
📈 What is it?
Revenue per employee indicates how much revenue a company generates on average per employee – a key measure of efficiency and productivity.
🧮 How is it calculated?
The employee count is typically taken from the most recent annual report.
🏛️ Why is it important?
This metric helps compare business models – especially between labor-intensive and technology-driven companies. A high value suggests automation, operational efficiency, or strong value creation per head.
🧮 Calculation
🎯 What does this mean for investors?
- A high revenue per employee indicates a scalable and margin-strong business model.
- A low figure may reflect labor-intensive operations or lower value-add.
- Especially helpful when comparing tech companies to industrial or service sectors.
Apyx Medical Corporation Stock Analysis
Analyst Opinions
12 Analysts have issued a Apyx Medical Corporation forecast:
Analyst Opinions
12 Analysts have issued a Apyx Medical Corporation forecast:
Apyx Medical Corporation Events
Past Events
|
NOV
9
2026 UBS Global Healthcare Conference
10 days ago
|
|
NOV
5
Q3 2026 Earnings Call
14 days ago
|
|
AUG
6
Q2 2026 Earnings Call
3 months ago
|
|
MAY
7
Q1 2026 Earnings Call
7 months ago
|
|
MAR
10
Q4 2025 Earnings Call
8 months ago
|
|
NOV
6
Q3 2025 Earnings Call
about one year ago
|
StocksGuide Free
Apyx Medical Corporation — 2026 UBS Global Healthcare Conference
1. Question Answer
Thanks for joining. And massive thank you to Charlie Goodwin for agreeing to do this from Apyx Medical's, CEO. Charlie, I think maybe what would be amazing if you could give people a little bit of a background to yourself. I know you've been at the firm for a while now, but a little bit of a history of you and then just a brief.
Perfect. Thank you very much, Patrick. Thanks for having us, and thanks to UBS for inviting us to the conference. My name is Charlie Goodwin. I'm the CEO of Apyx Medical. I have been the CEO of Apyx Medical since December of '17. And we transformed this company from a prior company was called Bovie Medical, which everybody has obviously heard about in the RF space. And in January of '19, we became Apyx Medical with a focus on surgical aesthetics. We had a product called Renuvion, a technology called Renuvion that was used after liposuction and body contouring for skin tightening. We built a business around that.
And then just last year, we launched AYON, which is a complete body contouring solution that has 2 forms of liposuction. It has dedicated fat transfer. It's obviously got the Bovie generator where -- so you could do all surgical procedures, and it has Renuvion for skin tightening to be able to complete the entire body contouring procedure with AYON. We launched that about a year ago. Just later this year, we finished a power-assisted handpiece for the second form of liposuction. So now AYON is 100% complete, and we are in the process of now trying to register that throughout the world, so we can sell it everywhere because right now, we're only commercialized it so far in the United States. And my background is I have been in medical device now for 35 years, although Patrick, you got to admit it doesn't look that long. You're looking at me.
Right.
But I actually have been in medical devices for 35 years, been all focused on the surgical side of things. As I came here to Apyx, that was the first time in aesthetics. And it's probably not a surprise that we're focused on the surgical side of aesthetics. And we think that Apyx can be the largest surgical company in aesthetics. We think surgery is incredibly relevant in aesthetics because we believe it is the only thing that provides durable and transformational results.
And we also believe that because of the disruption of the marketplace for the GLP-1 drugs, that most of those patients are going to benefit from a surgical intervention to get their bodies contoured back after the weight loss that they've had because of these drugs. And so we think that we are positioned incredibly well to be able to grow for many years to come. We're very proud that in this last earnings call that we just had on Thursday that the trailing last 4 months, we have got the EBITDA positive. So we've taken a small company, and we've dramatically lowered the burn that is there. And we think that with AYON and Renuvion, we can grow for a long, long time.
I definitely want to hit on the GLP-1 slide later. Pretty much everybody in the town I live is microdosing that, which is kind of entertaining. But maybe for those who are less familiar with Renuvion and Helium Plasma specifically as an approach, some of the background of the technology and the relative advantages versus other approaches might be helpful.
Okay. Renuvion is an amazing technology. And historically, it has been used to tighten the skin after a liposuction procedure. So if you think about the removal of fat for liposuction, the last thing you want to have happen is to not have that finish or not have that tight look. If you just do lipo without Renuvion, you can look much better in your clothes, but you won't look that great on the beach. And everybody wants to look really good on the beach. So Renuvion has done that. We've always believed in evidence-based medicine for Renuvion. And so I believe that Renuvion is the most research technology of its type in aesthetics. We've got over 100 clinical papers that talk about the safety and efficacy of Renuvion.
And then Renuvion is also a cold atmospheric plasma. I won't go into the science behind that, but it is being cold atmospheric plasma is being studied all throughout medicine. And there's 2 other studies that we have done. One just came out in September, but there's 2 other areas of Renuvion that are being used in aesthetics. The first is we did a study that if you pretreat an area with Renuvion before you do fat transfer, you get a 40% higher viability of the fat long term with that. And that has to do with the cold atmospheric plasma portion of Renuvion. And that becomes incredibly important, obviously, in something like a BBL, where you're going to take fat from other parts of the body and put it in the butt.
And one of the fastest-growing procedures that is out there is scarless Mastopexy, which is into the breast. And it's incredibly relevant in the GLP-1 drugs because when women lose weight, one of the places that they lose weight first is in their breast. And quite honestly, it's one of the last places they want to lose weight. And a lot of women don't want to have an implant. And so you take fat from part of the body, you put it in the breast and you help the aesthetics that way. So that is a study that we did that talks about another utility for Renuvion.
The one that just came out in September is the one I am most excited about because we have always heard from long-time Renuvion customers that the quality of the skin gets better after they use Renuvion. And we actually did a study on the face where we treated part of the face underneath with Renuvion and then we had a control area that wasn't treated with Renuvion. And it showed that Renuvion formed over 30% more elastin growth underneath the skin, which is huge because that is like Ponce de Leon and the fountain of youth. It is regenerative in nature to have your body produce more elastin. And so not only did it have 30% more elastin, it also had over 30% less inflammation also. So that is a study that just came out in September.
If you look at our total revenue, which I think this year is going to be about $54 million, about half of that is in the disposable Renuvion handpieces. So we do have a very nice reoccurring business of Renuvion. There's over 90,000 Renuvion procedures that are done every year. And so it's not a small number of procedures. And it has been something that has grown this business from 0 to where we are today. So we're very happy with what's happened with Renuvion, but we're incredibly excited about the future of Renuvion based on the clinical study -- the last 2 clinical studies that I talked about.
It's always nice to hear about the science, and you never bore me with it. I watch an hour long video about liquid hydrogen. So like I'm that kind of guy, so I get it. I mean maybe you could walk us through the AYON system and the appeal for the surgeons themselves and why they would pick that kind of solution?
So we obviously were the one technology company that had Renuvion, and we started to look as an organization where we could have the biggest impact on aesthetics. And as I mentioned before, we're a big believer of surgical aesthetics for the durable and transformational results for it. And when we started to look at the marketplace, there wasn't any meaningful innovation that had gone on in liposuction in almost 20 years. And the other side of it is it was incredibly fragmented market with a lot of smaller players. And in our opinion, it was an area that was ripe for disruption. And so what we did as a company is we went out and started to work with some of the top body contouring doctors in the world, and we basically gave them a blank slate and said, okay, from a technology point of view, what would you want to have improved from a workflow perspective, what would you want to have improved? What features are not there today that you would love to be able to see in a body contouring system?
And we had them design the entire system from scratch. We also took a look at pain points that they had from a reliability, usability, all of those types of things, huge list and gave it to our development team and our development team did a phenomenal job and developed AYON. So what is AYON? AYON is the ultimate body contouring system in the world today. It has 2 forms of liposuction. It's got ultrasonic liposuction and it's got power-assisted liposuction. It's got aspiration. It has infiltration. It has a closed loop for fat transfer. So you can take the fat out and put it back into the breast or the butt as we talked about before. It has an electrosurgical generator. So there is not a surgical procedure that the doctor cannot do in aesthetics with AYON. And so it really is the only surgical system that an aesthetic doctor needs to do any form of body contouring or any surgery there.
Every technology that is in AYON is better than the existing technologies today. And the workflow and other features it has like fluid warmers for the fluid that go into the patient are things that the doctors were having to do and having to do in a very cumbersome way before, and it wasn't very easy for them or their staff to do it. And so everything about the procedure has been enhanced and changed. And what we're seeing right now from the field in AYON is doctors are telling us that their patients are having less bruising and recovering faster because of the technologies that are in AYON. There is a definite workflow advantage and a synergy advantage to doing procedures quicker and faster for the doctor and their staff than they could do them before with the existing technologies.
And then the other thing is when you look at these body contouring procedures that the patients are seeking, there are really 2 things that are incredibly important to the patient. And those 2 things that the patient really cares about is they want an incredible result. They want their body to look amazing after it's done. And the second thing is they want it done as safely as possible. And if you really think about plastic and aesthetic surgery, they're the only surgeons that are competing globally for patients.
Patients will travel all over the world to have a procedure done if they think that they're going to get a smoking hot result and it's going to be done incredibly safe. And AYON helps the physician deliver on both of those things for the patient. And we're seeing doctors that are taking AYON and they're marketing it directly to the patient to be able to attract those patients into their practice to be able to have the latest and greatest technology to give the patient exactly what they want as far as the look of their body after and the reassurance that the doctor is using state-of-the-art technology to be able to provide it as safely as they possibly can. So that is what AYON is. That's a lot of long, long answer in AYON, but that is what AYON is.
So how much of the heavy lifting is then done on, say, capturing new patients from the physician selling the benefits, the false recovery time outside versus you guys doing patient awareness? Like where does the -- because aesthetics is a little unique in that there's really 2 people that you want to win over. It's a little bit unlike cardiology or whatever, which is a different mechanism.
Absolutely. It falls on both of us actually. It falls on the company to do that, to be able to talk and educate the consumer and to talk to the consumer about the choices that they have and the questions that they should be asking. And then obviously, it's the physician and their teams and their practices when that patient comes in the door and they're able to talk to the patient and present to them what their options are and what they think is the best option for them and why. So it falls on both of us.
Presumably, you have a subset of Renuvion customers who you could then approach with AYON and talk to them about that. Have we gone through most of that? Is there any of that left as a conversion?
There is still lots of that left. Yes. So if you look at the AYONs that we have sold so far, about 75% of those AYONs have been to Renuvion customers before and about 25% did not have any affiliation with Apyx or us before. So that is kind of the makeup. But if you look at our -- from our installed base of Renuvion, we've probably only upgraded about 15% of those customers. And part of the reason for that is we just did get approval of the power-assisted handpiece in May of this year. So even though portions of the AYON system have been out, the entire system wasn't completed until we just got to May. And about 70% of body contouring doctors use a power-assisted handpiece. And so it was an incredibly important piece of AYON to get to the marketplace. And we just got approval in May, and then we just were able to basically start shipping a lot of those in the September, October time frame.
Got it. I'm actually less familiar with the approval process, presumably it's like a 510(k), but it's separate for the system versus the handpiece. Is that?
So when we -- yes, when we did AYON, we -- the first approval that we got was for all of AYON and the ultrasonic portion of that. So we had the ultrasonic liposuction portion of that approved in May of last year. And then the plan was always to come with the power assisted as a second approval. And so it is a 510(k), and that's what we did. And everybody asked me the question, well, if it's 70% of the doctors use the power assist, why didn't you do that first? The reason being is just we could get the ultrasound to the market first. And so it was just from a speed perspective and the power assist took more time. And so we needed more time and development to be able to do it. And so that's why we prioritized it in that order.
I think you guys have talked about shifting into the hospital setting a little bit. Where are we at in that?
Well, right now, we're on a -- if they call us, we'll sell to them. So one of the things that we've always been as a company is our business has been 100% focused on the cash pay portion of that. And part of that was just because of Renuvion and customers would pay for Renuvion to be able to have that really nice look and hospitals and breast reconstruction market, that's not typically what they do. But in breast reconstruction, in all of those procedures, they all use liposuction. And so now that we have AYON, it has completely changed our offering into that marketplace. And we have had doctors that have called us to purchase AYON, and we have sold some AYONs into the hospital because of that reason. They've heard about it, they've read about it. They've seen the technology, and they obviously want to provide the best technology in that setting also. So we've sold some by accident is the best way that I can say that at this point in time.
And so now we, as a company, obviously need to figure out how we are going to go to market in the hospital setting. And obviously, there's options. We could find a partner to do it for us. We could do it through a direct sales channel. We could do it through an indirect sales channel. So those are the things that we are looking at as an organization to try to figure out the best way for us to be able to do that. But the nice thing is it's a brand-new market for us that we weren't exactly calling on, and that market is almost as big as the cash pay market in the United States. So that is -- it's a nice problem to have.
How do you place the system, how much support does that account then need subsequently? Does that differ by cash pay versus hospital or not, like?
Not really, no. The doctors and their teams are all used to these technologies. It's really just an in-service on the actual AYON itself and the differences of AYON versus the equipment that they're using and how it needs to function and how they need to use it. So it's really just that. And we do have a clinical team as part of Apyx. We've got some tremendous nurses that will go around and they'll do the in-services and they'll make sure that everybody understands how to use it and how to use it safely and effectively and all of that. And so it's not a huge lift from that aspect at all.
The -- I kind of want to pivot now back to that massive, the GLP-1 side of things because that is just a huge tailwind, I think, as a lot of people aware. We've seen it on the flip with bariatric surgery just having a really tough time. But obviously, there's downside to GLP-1 therapy and having a lot of loose skin, things like that. Maybe the people have sense for you as the longer-term vision of what's happening there and how that helps you.
So we think that the GLP-1 are have been the biggest disruption to the aesthetics market that the market has ever seen. And obviously, from a scale perspective, the GLP-1 drugs are just massive in comparison to the entire aesthetics market. And not only has it changed the companies, but it's changed the way that the doctors are having to talk and to practice and it's changed the procedures that they're having to do because they're having to do more combination procedures where they do body contouring and some incisional work because of the amount of weight loss that the patients are having with these drugs. And so we see this as not just a short-term change to the market.
We see this as a massive change to the market for many, many years to come because we see the use of these drugs actually increasing, not decreasing anytime soon. And if you really think about what's happened is because of the weight loss and because of taking the drug, most patients aren't going to benefit from a noninvasive treatment. They are going to need to have a more invasive treatment, whether that becomes liposuction and Renuvion or whether that becomes an incisional procedure or whether that becomes a combination of both to be able to get to the body to the way that they want it. McKinsey just did a study not that long ago that over 60% of these patients are going to be new to aesthetics. And so that is a massive amount of people that are going to be coming into the aesthetics market that are going to want to get their body contours.
The other thing about it is if you look at the aesthetics market, there's really a couple of markets in aesthetics. There's the MedSpa market where people have Botox and microneedling and all those types of things that are done by non-physicians. And then there's the surgical side of aesthetics where only surgeons are performing the treatment. And if you look at how the market is, is the MedSpa market tends to be lower price, lower dollar volume, a lot of times younger cost consumers. The surgical side tends to be a little bit older and a lot more well off. And so those are the same people a lot of times that are taking the GLP-1 drugs. And we believe that they've got the money, they've got the bandwidth to be able to get their bodies taken care of as they see fit.
So you see the Venn diagram of the GLP-1 patients intersecting probably quite nicely with when you would get your patients from. I guess the other question people always have in aesthetics is the economy and the macro side of things. But to your point, should we think that your patients tend to be a little bit more well off and older and therefore you, and you've got low penetration today, so there's like 2 effects. Is that fair?
That is incredibly right. That is exactly how we see it is. The patients that are going to want to get their body contoured are typically older, typically more well off, typically have had their children, typically, sometimes they've even gotten them through college and everything else. And now they just want to look as good as they feel. People are active for a lot more years in their lives. They're getting healthier. They're finding all the things about that. They're going to want their body to look that way. And that is exactly what we believe.
And more importantly, everybody wants to look better. Everybody wants to be the best version of themselves that they can possibly be. And we believe that surgery in aesthetics is really the only true thing that is durable in aesthetics and transformational. So it's really got those 2 things. There's a lot of things in aesthetics that aren't durable and aren't transformational. And we've seen that with technologies in the aesthetic space that were once here today gone tomorrow. Surgery is probably the only thing that is truly durable and will be for many, many, many years to come in aesthetics.
Interesting to hear you talk about being the best version of yourself. I don't know, between like Christmas and New Year, I try to be the worst version of myself, just to really degenerate. But the -- if you think about the bigger picture within aesthetics because as you said, you've been in the industry for a long time. Do you think like nowadays, the introduction of social media and all that stuff has just made people acutely aware because if I look at other categories that are tangential to yours, like take Bausch + Lomb, they've got a product that makes their eyes whiter, LUMIFY, which has just been like all this stuff is just still flying. Do you think the pressure in the social situation has just created people are just much more aware of how they look, I guess?
Well, I think that people have always, number one, cared of how they've looked. Now they just got a forum for it to be able to talk about it. I do think, though, I think your point is right on. I think that social media has made aesthetic surgery much more acceptable. There used to be a time where people would not admit that they had a procedure or that they had something or that they do anything. And now it has just become so much more socially acceptable that you've got actually influencers that will take you on their journey from when they go into the consultation to their recovery to everything else that it gives people a sense of what to expect, what to think about questions to ask. I mean that education is actually valuable in a lot of ways that never existed before because there was a situation to where you just didn't talk about it in like my parents generation, that was something you just wouldn't do. But now it's become so much more socially acceptable.
And I think it's like everything else that we've got in this world, there's a huge part of that, that is really good. And there's a downside to that, too. But that huge part that's really good is it allows people to understand what it is that they're going to potentially do, what they need to ask for, what they need to do, what they need to expect. And quite honestly, then how they should look afterwards. And so I think there's -- I think it's changed a lot, and I think it's changed -- it will change aesthetic surgery forever.
And I think that aesthetic surgery will be something that is incredibly mainstream. I mean if you really look at aesthetic surgery, this is all going to fit and to morph into wellness and longevity. And there's a huge push right now in aesthetics for wellness and longevity. And I think as you get more wellness and more longevity, it's going to be more important for -- to have you look the way that you think in your mind that you should look based on how you feel and everything else. And so I think this all ties together, and I think it's going to be a tremendous market for many years to come.
Presumably, for you guys, people's ability to filter how they look on their phones. And I think there's something like a line, right, where you can see how your teeth would look, and that's how they get you into the procedure. Same deal for you guys, people said look at photos themselves and then say, what might that look like? Presume that's quite a helpful funnel of driving incremental volumes over time.
There's no question about that. And the technology is going to exist for all of that. You're going to be able to scan your body and show what it looks like now and what it could look like in the future. And it really will be an amazing, amazing market with the things that are going on in aesthetics. It's tough right now because of the disruption, but that disruption, as you know, once everything settles out of that, then things really go.
So just -- I just want to pivot back to Power Lipo. Are you guys in full release now? Or is this a limited market release? Or what are we?
We are now in full release of Power Lipo. If you would have asked me a month ago, it would have been -- now we are in full release of Power Lipo. Yes. Any time you're going to start a new product, you got to get the supply chain up and running. You got to get manufacturing up and running. You've got all of those things that you've got to do. But the team did a wonderful job of getting through all of that. And now if you want an AYON, I can get you a Power Lipo tomorrow.
I do like to collect toys from all mt companies, so don't tempt me. I have a genomic sequencer in my office.
There you go.
So I definitely get on that side. And then when you're having those discussions with the accounts on Power Lipo coming out, do you think the uptake will be pretty strong in line with what you were hoping? And then there's obviously a benefit, obviously, from that being in full release to the more holistic portfolio overall. Like what's the feedback been?
Yes. The feedback from Power Lipo has been amazing. And one of the things that is really unique about our Power Lipo system is that the doctor can actually control the direction of the fat from the sterile field. Before with every other system, they would have to have a scrub nurse changing the flow of the pump every time. And now the doctor has complete control with a button right on the handpiece that they can either take the fat out or put the fat back in after it's been processed for the fat transfer. And so it is amazing that doctors didn't even know that, that was possible. And it's one of those things that now that doctors have seen it, they go, I can't be without that now.
And so for us, it's just a matter now of making sure that everybody understands exactly what AYON is, what it does and what all the technology is because the issue is when you see AYON, it is a beautiful s*** machine, but what you notice is that it's all in one. And that is the least impressive part of AYON, the technology that is actually in AYON in each one of the liposuctions and everything else that is in there is really the most important part and really the most impactful part for the doctors, their patients and their teams. But it's us telling them that story. It's other doctors talking to them that have it. So that word takes a while to actually get out, and that's the part that we're in right now. Obviously, we're commercialized in the United States, but we got to tell the story everywhere in the world, and we're working on registrations now.
Yes, I was going to say for the OUS market, there's still plenty of aesthetics going on. And to your point about medical tourism is very high. How are you thinking about the go-to like, I can imagine that the APAC, in particular, have massive markets there. And like how are you thinking about the OUS opportunity?
Yes. The OUS opportunity is gigantic. If you think about the United States, there's about 15,000 clinicians that are doing body contouring. There's about 30,000 outside the United States. So the market is twice as big outside the United States. And the market is actually a little bit different outside the United States in that most of the procedures, especially in Europe, for example, and even in Brazil and other places are actually done in the hospital. The cosmetic procedures are done in the hospital, and they're done by surgeons and teams of surgeons.
And one of the things that we haven't talked about with AYON, one of the features of it is it has simultaneous activation where a doctor and their team can be doing 4 distinct things at the exact same time or 2 of the -- they can have 2 power lipos taking out fat at the exact same time. So the benefit actually like in places like Europe, where the doctor and his team is that much greater because now they can do the procedure that much faster. And it is so much better for the patient because they're under anesthesia for less time. The procedure is half the time and everything like that. So it has huge unique advantages in certain countries outside the United States because a lot of times in the U.S., it's just done by one doctor.
Have you seen a change in the -- or you expect to see a change in the patient mix over time? I mean, obviously, GLP-1s across a wide range of patients. But I mean, can you paint -- you hinted it, but can you paint what the average patient is today? I mean, do you know your male, female mix, the average kind of age? And is that likely to stay stable? Or do you think that's going to change over time?
Yes. It's interesting because, yes, the average patient is actually female, about 85% of them are female. And most of the age is typically around 45 is around the typical age. And we see the age growing on both sides, older and younger. And so we actually see more and more people having procedures from a wider higher and lower. And then the other thing that is there is men now are becoming more interested in these procedures as they lose their weight and they want to come in. So we're seeing growth from the male side, too. So I think it's just expanding the overall market. And remember, the McKinsey stat, 60% of these people are new to aesthetics. And that it's huge. Net new on that side. Yes.
And then I mean the other thing that's unusual about GLP-1s is a good chunk of patients will end up regaining the weight and losing it and regain the weight and losing it, which creates a sort of -- I can't imagine what that does to your skin and things like that. But how do you see that fitting into the overall?
Well, I think that has been the biggest thing that we thought initially is we thought that these patients would take the drug, they would lose the weight and they would have surgery right away. And I think the part that you're talking about is, I think everybody -- so first thing when that happens is most plastic surgeons will make you wait 6 months if you're going to get off the drug to make sure that you can keep the weight off before they're going to do a procedure. So that is -- most of the plastic surgeons are doing that right now. The second thing is, I think from a person's point of view is you have to figure out what you're going to do with GLP-1 drugs. Are you going to take them, lose the weight, get off, change your lifestyle and keep it that way? Or are you going to do what a lot of people are doing now is losing the weight and then microdosing the GLP-1 drug potentially for the rest of your life to be able to do that. And so those are all the things that are happening in the marketplace and everybody is trying to -- from a consumer point of view, is figuring out what is best for them.
I think trying to manage that is going to be an interesting challenge. Final thing, you have conversations with investors in the public markets and a lot of other things. Is there anything that people don't ask you that they should or where you think that there's a miscalibration between how the market views you and aesthetics relative to how you view it internally? Anything like that?
Yes, I do. And I think that because of the huge disruption of the GLP-1 drugs, it's made the market incredibly complicated right now. And I think there's a lot of misconception from investors and everybody from what the future of this market is going to be. And if you look at it right now, a lot of people don't want to invest in the aesthetics market. I personally think that is a tremendous mistake because I think any time that there is major disruption in the marketplace, there is major opportunity in the marketplace.
And I think what you've seen is you've seen a change in the providers. You've seen a change in the patients. You've seen a change in the companies. And there are companies that don't have the right technologies or the right products to be able to address this class of patients. And there are some providers that quite honestly, aren't doing as good a job of communicating to that group either. And I think as this gets all sorted out, there's going to be tremendous winners on the provider side, and there's going to be tremendous winners on the company side that have the right technologies to be able to address this patient group and provide what they need.
Sounds like an opportunity for us. Great. Thanks.
Thank you. Appreciate it a lot.
Thank you.
Apyx Medical Corporation — Q3 2026 Earnings Call
1. Management Discussion
[Operator Instructions] As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Jeremy Feffer from LifeSci Advisors. Please go ahead.
Thank you, and welcome, everyone, to our third quarter 2026 earnings call. Representing the company on the call are Charlie Goodwin, Chief Executive Officer, and Matt Hill, Chief Financial Officer of Apyx. Before we begin, I would like to remind everyone that our remarks and responses to your questions today may contain forward-looking statements that are based on the current expectations of management and involve inherent risks and uncertainties that could cause actual results to differ materially from those indicated, including, without limitation, those identified in the Risk Factors section of our most recent annual report on Form 10-K, our most recent 10-Q filing, and the company's other filings with the Securities and Exchange Commission. Such factors may be updated from time to time in our filings with the SEC, which are available on our website. We undertake no obligation to publicly update or revise our forward-looking statements as a result of new information, future events, or otherwise.
This call will also include references to certain financial measures that are not calculated in accordance with generally accepted accounting principles, or GAAP. We generally refer to these as non-GAAP financial measures. Reconciliations of these non-GAAP financial measures to the most comparable measures calculated and presented in accordance with GAAP are available in the earnings press release on the Investor Relations portion of our website.
I would now like to turn the call over to Mr. Charlie Goodwin, Apyx Medical's President and Chief Executive Officer. Please go ahead.
Thank you, Jeremy, and thank you all for joining us today. Per our usual format on these quarterly calls, I will begin with a review of our performance over the past several months, and then turn the call over to Matt for a review of our third quarter 2026 financial results, along with our guidance for the full year 2026. We will then open the call for your questions. Let me begin with a review of a few key highlights from our third quarter 2026 performance. We delivered another quarter of strong year-over-year growth with total revenue of $14 million, an increase of 9% compared with the third quarter of 2025. Growth was driven primarily by sales of AYON in the United States and Renuvion outside the United States, reflecting continued demand for our body contouring technologies. For the 3 and 9 months ended September 30, 2026, our Surgical Aesthetics segment grew over 17% and 26%, respectively, as compared to the same periods last year.
We are pleased by the progress we have made with AYON in the 1 year since its full commercial launch. During this time, we have continued to build awareness of the platform and demonstrate the value of bringing fat removal, closed-loop contouring, Renuvion tissue contraction, and electrosurgical capabilities together in 1 integrated system. We are building on a foundation with the broader commercial rollout of AYON's power liposuction capability consistent with the plans we outlined last quarter. Power liposuction uses a reciprocating cannula to support more efficient fat removal while reducing the physical effort required of the surgeon. We estimate approximately 70% of plastic surgeons use power liposuction, making this an important addition that broadens AYON's appeal. Therefore, the recent clearance and commercial launch of power liposuction was a pivotal catalyst in driving AYON's adoption. While the rollout remains in the early stages, feedback from surgeons has been very positive.
PowerLipo was designed directly into every AYON, and activation requires only a simple software update and the purchase of the handpiece and cannula. Clinicians can seamlessly deploy the full clinical AYON solution with no downtime. The legacy liposuction products on the market haven't moved the needle on safety and efficacy in 2 decades. The AYON system was designed by surgeons to specifically close these clinical gaps. By embedding next-generation safety and workflow optimization into a single, elegant system, we believe AYON establishes a new benchmark for surgical performance. It is uniquely positioned to be the global standard of care for plastic surgeons. Renuvion remains central to our strategy, both as a standalone system and as an integrated part of AYON. Its tissue contraction capability complements fat removal, helping surgeons address skin laxity that remains after liposuction or significant weight loss.
Continued demand for AYON and Renuvion reflects the value surgeons see in having these complementary technologies available for their patients. Our commercial strategy is supported by our continued commitment to building clinical evidence. Last quarter, we discussed studies reporting higher patient satisfaction and lower rates of abdominoplasty and surgical revision with Renuvion plus liposuction compared with liposuction alone, as well as improvements in cellulite appearance and skin laxity following combined Avéli and Renuvion treatment. In September, we added to this evidence with a prospective study evaluating Renuvion's effect on biological markers associated with skin quality published in Plastic and Reconstructive Surgery – Global Open. The study enrolled 7 patients undergoing facelift surgery with 6 completing the 6-month follow-up. Tissue analysis at the visit showed 30% greater elastin fiber density and 34% less inflammation in treated tissue compared to untreated control areas. All 6 patients reported improvements in skin quality and satisfaction with their outcomes.
These findings add direct human tissue evidence supporting the improvements surgeons and patients have observed with Renuvion and reinforce the value of evaluating tissue quality alongside tissue contraction. We believe this is an important consideration in body contouring where achieving the desired results depends not only on removing the fat, but also addressing the quality and laxity of the skin that remains. Looking ahead, the continued adoption of GLP-1 medications is reshaping the body contouring patient population and creating what we believe is a meaningful long-term opportunity for our business. While these therapies are helping a growing number of patients achieve substantial weight loss, many are left with loose or lax skin and residual areas of fat that they want to address. As these patients reach or approach their target weight, we believe many will seek procedures that address these concerns more comprehensively. By combining advanced fat removal with Renuvion's tissue contraction capabilities, Apyx positions us to help surgeons meet these needs. Our focus remains on transitioning this opportunity into broader adoption through continued commercial execution.
Before I turn the call over to Matt, I want to recognize the Apyx team. We have successfully achieved our product development, regulatory, and sales goals, all while maintaining strict cost discipline. To that end, I am pleased to report that on a cumulative trailing 12-month basis, the company has achieved positive EBITDA. Now I will turn the call over to Matt for a review of our third quarter 2026 financial results in more detail along with our financial guidance for 2026.
Thanks, Charlie. Before I get started, please note that all references to our third quarter financial results will be on a GAAP and a year-over-year basis unless noted otherwise. As Charlie mentioned, total revenue for the third quarter of '26 increased 9% to $14 million compared to $12.9 million in the prior year period. Revenue for the Surgical Aesthetics segment increased 17% or $1.9 million, to $13 million, compared to $11.1 million for the prior year period. This growth was driven by sales of AYON as we commenced our commercial launch in the third quarter of '25 and increased sales of generators internationally. These increases were partially offset by decreases in domestic sales of standalone generators and sales of single-use handpieces globally. Turning to the OEM segment, sales decreased 41.5% or approximately $0.7 million, to $1.1 million, for the third quarter of '26 compared to $1.8 million for the third quarter of '25. The decrease in OEM sales was due to a decrease in sales volume to existing customers.
With the increased focus on Surgical Aesthetics, we expect OEM segment revenue will decrease for the year. Domestic revenue increased 4% year-over-year to $9.7 million, and international revenue increased 22% year-over-year to $4.3 million for the third quarter of 2026. Gross profit for the third quarter of '26 increased 9% to $9 million, compared with $8.3 million in the prior year period. Gross profit margin for the third quarter of '26 decreased to 64.2% compared to 64.4% in the prior year period. The decrease is primarily attributable to geographic mix with international sales comprising a higher percentage of total sales and product mix within both the Surgical Aesthetics and OEM segments. These decreases were partially offset by an increase due to mix between our segments with Surgical Aesthetics comprising a higher percentage of total sales.
Operating expenses increased to $9.6 million for the third quarter of '26 compared to $9.1 million for the prior year period. The increase was mostly driven by a $0.4 million increase in salaries and related costs and a $0.2 million increase in selling, general, and administrative expenses, which was partially offset by a $0.2 million decrease in professional services.
Loss from operations was $0.6 million, compared with a loss from operations of $0.8 million for the third quarter of 2025. Net loss attributable to shareholders was $1.8 million, or $0.04 per share, for the third quarter of '26, compared with $2 million or $0.05 per share in the prior year period. Adjusted EBITDA was $0.4 million for the third quarter of '26, compared to an adjusted EBITDA loss of $0.1 million for the third quarter of '25. As a reminder, we provided detailed reconciliation from net loss attributable to stockholders to non-GAAP adjusted EBITDA in our earnings press release.
For the 3 months ended September 30, 2026, net cash used in operating activities was $1.6 million compared to $3.5 million used in the prior year period. The decrease was primarily due to changes in working capital, combined with a reduction in net loss. As of September 30, 2026, the company had cash and cash equivalents of $25.8 million.
We have maintained a solid cash position, managing to an average cash burn of approximately $2 million a quarter this year, providing substantial flexibility to support our ongoing operations and execute our strategic plan. As you can see from our financial performance, we're very focused on growing the top line while prudently holding the line on operating expenses. Our continued focus on operating discipline, cash management, and financial performance positions us to navigate our upcoming obligations while maintaining our commitment to long-term value creation.
Turning to our 2026 guidance, we're reaffirming our full-year revenue guidance in the range of $59 million to $60 million compared with $52.8 million reported for the year ended December 31, 2025. Our guidance continues to assume Surgical Aesthetics segment revenue in the range of $54 million to $55 million, compared with approximately $45.3 million for 2025, and OEM revenue of approximately $5 million, compared with approximately $7.5 million for 2025. In addition, we now expect gross margins in the range of 63% to 64% and updated our total operating expense targets in the range of $41 million to $42.5 million for the full year. Previously, we stated operating expenses would be less than $45 million.
This completes our prepared remarks. Charlie and I will now open the call for questions. Operator.
[Operator Instructions] Your first question comes from the line of Alex Fuhrman with Loop Capital Markets. Please go ahead.
2. Question Answer
Can you talk a little bit more about the lower operating expense target for the year and what's driving the improved profitability here? Obviously, it sounds like very strong demand here, especially with the addition of power lipo here, but would love to get a better understanding of the improved profitability here as well.
Yes. No, I appreciate the question. Look, we've stated that we want to get this business to profitability as quickly as we can, and we're very proud of the effort that the team has put forward. For the last trailing 4 quarters, we're actually EBITDA positive. And so we've done a very good job of growing the top line, but also managing the bottom line. And you're seeing the growth go straight to the bottom line, and that's why you get the improvement. We had always stated at the beginning of the year that we weren't going to spend more than $45 million, and obviously through the first 3 quarters, we're way under that. And so now we just tightened that range of what we will spend between now and the end of the year.
Okay, that's really helpful. And then, obviously, not trying to get you to give us formal guidance for next year or anything, but just can you give us a little bit of understanding of just how to frame up where you are in the rollout of the new all-in-one system? Is that expected to be a continued tailwind into the first half of next year?
Well, I would say that the tailwind for all-in-one is for multiple years. Remember, we're just getting started in the United States. We actually just got PowerLipo out to everybody that had bought it. And so we think that AYON will have growth for a lot of years to come. And the other side of that is right now we are only selling it in the United States. And obviously we're working on registration in a lot of the key markets outside the United States and would expect to have those at some point to be able to start selling AYON on a worldwide basis. Doctors all over the world are seeing AYON at the show. They're talking about it. They're hearing about it. And, you know, we're just excited to get it registered and to get it out there.
Yes, that'll be really exciting to see that. Thank you, Charlie, and congratulations again on the strong results.
Thanks, Alex.
Your next question comes from the line of Sam Eiber with BTIG. Please go ahead.
Maybe just following up on that last question, are there any key markets we should be looking out for in terms of timelines when AYON might get the necessary regulatory approvals? I know Renuvion has been doing well in certain markets, but curious if you're able to give us any timelines on AYON and some of the larger OUS markets you play in today.
Yes, timelines. The answer to that is no. Obviously, when we get registration in some of these key areas, we'll obviously let the market know if it's important. But obviously the markets that we were really after and really want right away are obviously Europe, the Middle East, and then key countries in Latin America. And those key countries in Latin America are namely Brazil, Colombia, and Mexico.
Okay, very good. Fair enough. And then maybe I can just use a follow-up question here on what's resonating maybe more with some of the doctors that have adopted AYON at this point. Is it more so the clinical benefits that they're seeing? Is it the economics on the faster procedures and greater patient throughput? Or maybe it's a combination of the two, but curious what you're hearing from the field.
Yes, it's all of the above. Doctors are really noticing the technological advances in the liposuction, and the doctors that see it and have it are talking a lot about it. They are seeing that their patients actually recover faster because they have less bruising and less downtime from traditional lipo that they were using before. And so there's definitely that clinical aspect of it, and having the integrated system for fat transfer and everything else is key to them. And there are doctors that are using it to actually bring in new patients and talk to patients that they've got the latest and greatest technology and are able to either convert more patients into having procedures with them or even in some cases charging more for those procedures because they're using the latest and greatest technology. And then there's the whole efficiency piece for the doctors and their teams where they're able to save time and do that. And so Apyx has a lot of drivers for the doctors, their patients, and their practices.
It's now our job on the commercial side to make sure that everybody understands that—the doctors themselves, their staff, and the patients also. So we've still got work to do from a worldwide basis, but we are even more excited as we sit here today that we think that AYON will be the standard of care for body contouring all over the world. It really is being received that well in the field.
Okay, very good. Thanks for taking the questions, guys.
Your next question comes from the line of Tollef Kohrman with Craig-Hallum. Please go ahead.
So for AYON growth, how much of that was competitive conversions? And then for my second question, could you speak to the pipeline of PowerLipo? Thank you very much.
Yes, so I'll do the second one first. So PowerLipo, we were able to fill all the orders of PowerLipo just within the end of this last quarter. So everybody that had a PowerLipo system could actually get their handpiece, at least 1 of them. And I think now we've been able to get everybody all of theirs since then. And now is the first time that if you actually bought an AYON today, you could actually get PowerLipo with it. Okay. So that's the first one. As far as new customers, if you look at where we've done so far, about 75% of our AYON sales have been to existing Renuvion customers and about 25% to brand-new customers that have never been part of Apyx.
Great. Thank you.
Your next question comes from the line of Danny Stauder with Citizens JMP. Please go ahead.
I wanted to ask on fourth quarter, how should we be thinking about capital versus handpiece mix in terms of what's implied for fourth quarter sales? And as we think out to 2027, what's a good way to frame that, just considering some of the puts and takes we saw in 2026? Thank you.
Yes, so if you look at handpieces in particular, it's always tough to look at it on a quarter-by-quarter basis. We obviously look at it on a year-by-year basis because it depends on whether some large customers when they place their order to where it is. And so for the first 3 quarters from a handpiece perspective, we're right where we thought we were going to be, and we would expect Q4 obviously to be a very good handpiece quarter because that's where the greatest number of procedures are done in Q4 as opposed to Q3. So we think that Q4 will be a good handpiece quarter as well as a good capital quarter. It's always our best capital quarter. And so we're looking for both of those things to happen.
As far as the comparison in Q4, remember that last year we started pre-selling AYON in May when we got approval. And so we were selling AYONs basically for over half of a year, and we didn't actually ship those AYONs until Q3 and Q4. So from a comparison basis, there were 6 months of sales that were put into the last quarter, basically. So from a comparison, it's not an apple-to-an-apple comparison on a regular quarter, but that's the last quarter of this. And then as we move into '27, obviously the comparisons will be a lot easier to go after.
That's really helpful. Thank you. And then just 1 follow-up on some of the terms of the international opportunity. Just in terms of AYON, could you talk about those markets? I mean, is that 70% of plastic surgeons using power lipo, is that consistent abroad? And is there any reason that AYON might be more or less attractive in some of these international markets, just depending on the different trends and idiosyncratic characteristics there? Thank you.
Yes, no, it's a good question because there are some differences there. Power lipo is about the same. That is not different. But what is different in Europe especially and in various other countries is a lot of the liposuctions are done in the hospital setting and done by teams of doctors. And that makes Apyx even that much more of a value to the doctors and their teams because of the simultaneous activation. Remember, you can do up to 4 things at the same time with AYON. So that simultaneous activation is a huge benefit in places like Europe where doctors and their teams do that. The other side of it, too, is because they're done in the hospital, a lot of the reconstructive doctors can be using AYON also. And that is an area that, quite honestly, they weren't really using Renuvion before. Now they're going to get exposure to Renuvion, too, on the reconstructive market. And so the reconstructive market is obviously an upside for us all over the world because it's really not a market that we have called on before. So there are some differences outside the United States because of where the body contouring procedures are done.
Great. Thanks so much for the question. Thank you.
Your next question comes from the line of Yi Chen with H.C. Wainwright. Please go ahead.
Good morning, this is Katie on for Yi. Thinking about AYON, for the systems that were installed earlier in the launch, do you find that customers are adopting the full workflow or selectively using different pieces of it, using Renuvion tissue contraction in a greater proportion of their cases? And what kind of gives you a clue that one of these customers is going to be a broader utilizer versus more selective?
Yes, so the answer to that is yes, more doctors are using the full suite of AYON, where we're seeing that especially is on the 2 different liposuctions. There's a lot of doctors that only used power liposuction and didn't have ultrasonic liposuction, and now we're seeing them use the ultrasonic liposuction also because it is a great tool for them to use in these procedures. So we are seeing that. As far as the Renuvion usage, as I stated earlier, about 75% of the AYONs that we've sold have been to Renuvion customers, and obviously they were using Renuvion before, and so that utilization is basically the same that it was. But where we are obviously seeing an uptick in Renuvion and them using the whole system is into the 25% of those that are new customers, new to Apyx. And we know that they're using Renuvion obviously because they're buying handpieces.
Quick follow-up, you had at 1 point mentioned a mechanism paper that will be published for Renuvion. Do you guys have any update on that?
Yes, that paper was—I don't think it was a mechanism paper. I think it was the paper that we highlighted in the prepared remarks. It was for skin quality. And if you look at Renuvion, we have done a very good job of publishing and talking about Renuvion for skin retraction, okay, and that is obviously very important, skin tightening. It's used after liposuction, it's used in body contouring, and that will remain obviously important. But we've done 2 other studies that show versatility of Renuvion itself, and 1 is the pretreatment of areas before fat transfer. And if you pre-treat the area with Renuvion before fat transfer, we have papers that show up to 40% higher retention of the fat graft. And so that is incredibly important when you're doing fat transfer.
And then the last part of that was the study that just came out in September that talked about skin quality. And that skin quality is incredibly important and we think is going to be a driver for Renuvion and new users for Renuvion because the skin is your largest organ. And as you're doing the skin tightening, what actually helps is if the quality of your skin can get better. And in this study, we had over a 30% improvement of elastin and about the same improvement in inflammation, and that improves the quality of the skin. And there hasn't been anything that has shown an improvement in elastin out there. So we think that that is going to be a very important paper for us and to keep talking about how Renuvion will keep being a driver of this business for many years to come also.
Thank you very much.
Your next question comes from the line of Jeremy Pearlman with Maxim Group. Please go ahead.
Just firstly, are there any remaining investments that are either planned or required to support AYON now that you've moved into the full commercial launch?
Yes. Now that we've made full commercial launch, now we've made all the investments that we're going to make for that. The only thing that we have ever mentioned before is, as I alluded to on 1 of the other questions, there is an opportunity in the reconstructive space, in the hospitals, in the United States, and we need to figure out how we're going to actually do that—more on that when it comes. But as far as investments come for this year, that is all baked into what we're doing. And then we've stated that getting to profitability for this company is incredibly important for us, and we're going to do it as fast as we can.
Okay, understood. And then just another question relating, maybe you can help us understand some of the divergence between domestic revenue grew this year only 4% and then international was 22% this quarter. So is that just because of the way that, you know, the winding down of the OEM business and then the transition from the limited to the full commercial launch, which is a timing issue and due? Should we expect that gap to be covered up by the domestic revenue going forward? Thanks.
Yes. So if you remember from our guidance, we've given guidance for the year that we will grow the Surgical Aesthetics business 20%, and we're at 26%, I think, after 3 quarters. And so what you're seeing in the U.S. business is, as I stated last year when we launched AYON, we got approval in May, and we started to sell AYON units that we could not ship until September, October, November, and December. So when you're looking at a comparison, all of the months that we've had before September, there was no AYON in that number. And now you're getting AYON in that number for September, October, November, and December. And that's why the growth rate appears to be going down. It is from a mathematical point of view, but we were selling AYONs all last year and shipped them all just in 4 months. So that's really the difference and why you're seeing that now in the third quarter.
And then obviously in the fourth quarter, you'll see that the growth rate in the United States won't be as high either because of those comparisons of AYON that were shipped in October, November, and December. As far as outside the United States, that still remains to—especially Korea has been having a very good year, their first year, obviously, launching Renuvion. And that's where a lot of the growth is from outside the United States.
Okay. Thank you for answering my question. I'll hop back in the queue.
I am showing no further questions at this time. This concludes our question-and-answer session. I will now hand the conference back to Charlie Goodwin for his closing comments.
Thank you, everybody, for joining us today. We are pleased with the momentum in the business this quarter and look forward to executing on the expanded commercial strategy we discussed as we continue to build market share for the AYON platform. I appreciate the continued support of our shareholders, our staff, and thank you all for joining the call today. Thank you.
Today's conference call for Apyx Medical has now concluded. Thank you for your participation. You may now disconnect.
This live transcript is auto-generated without human intervention or review.
Apyx Medical Corporation — Q2 2026 Earnings Call
1. Management Discussion
Good afternoon, ladies and gentlemen, and welcome to the Apyx Medical 2Q '26 Earnings Conference Call. [Operator Instructions ] This call is being recorded on Thursday, August 6, 2026. I would now like to turn the conference over to Jeremy Feffer, LifeSci Advisors. Please go ahead.
Thank you, and welcome, everyone, to our second quarter 2026 earnings call. Representing the company on the call are Charlie Goodwin, Chief Executive Officer; and Matt Hill, Chief Financial Officer of Apyx. Before we begin, I would like to remind everyone that our remarks and responses to your questions today may contain forward-looking statements. That are based on the current expectations of management and involve inherent risks and uncertainties that could cause actual results to differ materially from those indicated.
Including, without limitation, those identified in the Risk Factors section of our most recent annual report on Form 10-K, our most recent 10-Q filing and the company's other filings with the Securities and Exchange Commission. Such factors may be updated from time to time in our filings with the SEC, which are available on our website. We undertake no obligation to publicly update or revise our forward-looking statements as a result of new information, future events or otherwise.
This call will also include references to certain financial measures that are not calculated in accordance with generally accepted accounting principles or GAAP. We generally refer to these as non-GAAP financial measures. Reconciliations of those non-GAAP financial measures to the most comparable measures calculated and presented in accordance with GAAP are available in the earnings press release on the Investor Relations portion of our website. I would now like to turn the call over to Mr. Charlie Goodwin, Apyx Medical's President and Chief Executive Officer. Please go ahead.
Thank you, Jeremy, and thank you all for joining us today. For our usual format on these quarterly calls, I will begin with a review of our performance over the past several months and then turn the call over to Matt for a review of our second quarter 2026 financial results, along with our guidance for full year 2026. We will then open the call for questions. Let me begin with a review of a few key highlights from our second quarter 2026 performance.
We reported quarterly revenue of $13.9 million compared to $11.4 million in the same period last year, an increase of 22%. This growth was driven by a 28% increase in sales of our Surgical Aesthetics products to $12.4 million for the second quarter, primarily attributable to sales of our AYON Body Contouring System, increased Renuvion generator sales internationally and increased volume of single-use handpieces domestically. This marks our fourth consecutive quarter of AYON sales following its full commercial launch in September of 2025, and we are pleased to see increasing awareness of and demand for the platform across U.S. market.
U.S. surgeons are increasingly recognizing the value of our integrated all-in-one body contouring platform, which combines the core technologies they rely on every single day into a single streamlined system. We believe the growing adoption reinforces AYON's differentiated value proposition. We recently took another important step in expanding AYON's capabilities during the quarter when we received expanded 510(k) clearance from the FDA to add power liposuction to the platform. Power liposuction uses a reciprocating cannula to support more efficient fat removal while reducing the physical effort required of the surgeon.
Since receiving clearance, we conducted a limited commercial launch of the reusable power liposuction handpiece with key surgeons in targeted geographies. Based on positive feedback, we commenced initial commercial shipments in June of 2026. Overall, the sales and interest that we are seeing in AYON comes at an important time for the body contouring market. As we have discussed on prior calls, the continued rapid adoption of GLP-1 medications is reshaping the patient population and creating what we believe will be a meaningful long-term opportunity for our business.
While these therapies are helping a growing number of patients achieve significant weight loss, many are left with loose or lax skin that cannot be adequately addressed through nonsurgical treatments. Once these patients reach or approach their target weight, we believe many will seek procedures to address skin laxity, excess fat and overall body contouring in a more comprehensive manner. AYON seamlessly combines advanced fat removal technologies, Renuvion's tissue contraction and electrosurgical capabilities and empower surgeons to deliver the most comprehensive body contouring treatments for patients while positioning Apyx to address this growing market.
We believe in science-based medicine and our clinical strategy is an important part of establishing that value proposition. During the quarter, a retrospective study of 113 patients showed that a combination procedure using Renuvion and liposuction was associated with statistically significantly higher patient satisfaction, lower rates of abdominoplasty and surgical revision and a comparable complication rate versus procedures that use liposuction alone. These findings are important because they suggest that Renuvion may help surgeons deliver a more satisfying aesthetic outcome while potentially reducing the need for more invasive or follow-on procedures without increasing the observed complication rate.
We also reported data from prospective study evaluating a single session treatment combining Avéli and Renuvion. The study demonstrated visible improvements in cellulite and skin laxity, including measurable reductions in dimple volume, surface area and depth. In a subset of patients, histological analysis also showed increases in collagen and elastin through 180 days, providing evidence of progressive tissue remodeling following treatment. Together, these peer-reviewed publications add to the clinical foundation supporting Renuvion and demonstrate its potential value across a broader range of aesthetic body contouring procedures.
In addition, the publications reinforce the important point that as patients' needs become more complex, surgeons increasingly require technologies that can address not only fat removal, but also skin quality, laxity and structural factors that influence the final aesthetic result. We also took the opportunity this quarter to build broader awareness of our platform, showcasing Renuvion and AYON at Miami Swim Week through our Body by Apex showcase. The event featured real Renuvion patients sharing their treatment journeys and walking the runway, allowing us to highlight the aesthetic outcomes and the self-confidence those patients gain from their procedures.
This year's event underscored the progress we have made since last summer. At that time, AYON was still in the early stages of its commercial journey. This year, we returned with a commercially available platform supported by growing physician engagement, real-world experience and enhanced capabilities through the FDA clearance of power liposuction, which has resulted in AYON gaining traction across the market. Together, those milestones reflect the disciplined execution of our commercial strategy and reinforce the foundation of the opportunity ahead.
These accomplishments demonstrate the progress we are making in executing our commercial strategy and reinforce our confidence in the long-term opportunity for our cohesive platform of AYON and Renuvion. Before I wrap up, I would like to briefly touch on our recent announcement that Stavros Vizirgianakis has been appointed Executive Chairman of our Board of Directors. Over the past 2 years, Stavros has become an increasingly important partner to both our Board and management team. He has been deeply engaged in helping shape our strategic priorities, supporting key financing initiatives and strengthening our operational focus and providing valuable guidance as we execute our commercial strategy.
Formalizing his role as Executive Chairman recognizes the level of involvement he already has within the company and reflects our shared commitment to creating long-term shareholder value. Stavros brings decades of leadership experience and extensive industry network and a proven track record of building and growing health care businesses. I look forward to continuing to work closely with him as we execute on the significant opportunities ahead for Apyx. I will now turn the call over to Matt for a review of our second quarter 2026 financial results in more detail, along with our financial guidance for 2026.
Thank you, Charlie. Before I get started, please note that all references to our second quarter financial results will be on a GAAP and year-over-year basis, unless noted otherwise. As Charlie mentioned, total revenue for the second quarter of '26 increased 22% to $13.9 million compared to $11.4 million in the prior year period. Revenue for the Surgical Aesthetics segment increased 28% or $2.7 million to $12.4 million compared to $9.7 million for the prior year period.
This growth was driven by sales of AYON, increased sales of generators internationally and increased volume of single-use handpieces domestically. Turning to the OEM segment. Sales decreased 12% or approximately $0.2 million to $1.5 million for the second quarter of '26 compared to $1.7 million for the second quarter of '25. The decrease in OEM sales was due to a decrease in sales volume to existing customers. With the increased focus on surgical aesthetics, we continue to expect our OEM segment revenue will decrease for the year, and this trend will continue over time.
Domestic revenue increased 21% year-over-year to $9.4 million and international revenue increased 24% year-over-year to $4.5 million for the second quarter of '26. Gross profit for the second quarter '26 increased 25% to $8.9 million compared with $7.1 million in the prior year period. Gross profit margin for the second quarter of '26 increased to 63.9% compared to 62.3% in the prior year period. The increase in gross margin was primarily attributable to mix between our segments with Surgical Aesthetics comprising a higher percentage of total sales and product mix within our OEM segment.
This was partially offset by tariffs that began affecting us in the second half of 2025. Operating expenses increased to $10.7 million for the second quarter of '26 compared to $9.7 million for the prior year period. The increase was driven by $1.0 million increase in selling, general and administrative expenses and $0.3 million increase in salaries and related costs, partially offset by a $0.3 million decrease in professional services. Loss from operations was $1.8 million compared with a loss from operations of $2.6 million for the second quarter of '25.
Net loss attributable to stockholders was $3.2 million or $0.07 per share for the second quarter of '26 compared with $3.8 million or $0.09 per share in the prior year period. Adjusted EBITDA loss was $0.7 million for the second quarter of '26 compared to an adjusted EBITDA loss of $2.0 million in the second quarter of '25. As a reminder, we provide a detailed reconciliation from the net loss attributable to stockholders to non-GAAP adjusted EBITDA in our earnings press release. For the 3 months ended June 30, 2026, net cash used in operating activities was $3.5 million compared to $1.2 million used in the prior year period.
The increase was primarily due to changes in working capital, partially offset by a reduction in operating loss. As of June 30, 2026, the company had cash and cash equivalents of $27.6 million. We believe, based on our projections, including uptake of the AYON platform, working capital management and our strict cost controls, we expect to maintain sufficient liquidity into 2028. We are focused on growing sales, managing expenses and getting to cash flow positive as quickly as possible. Turning to our 2026 guidance.
We are reaffirming our full year total revenue guidance in the range of $59.0 million to $60.0 million compared with $52.8 million reported for the year ended December 31, 2025. Our guidance continues to assume Surgical Aesthetics segment revenue in the range of $54.0 million to $55.0 million compared with approximately $45.3 million for 2025, and OEM revenue of approximately $5.0 million compared with approximately $7.5 million for 2025. In addition, we continue to expect gross margins in the range of 62% to 63% and total operating expenses not to exceed $45.0 million for the full year. This completes our prepared remarks. Charlie and I will now open the call for questions. Operator?
[Operator Instructions] We will now take our first question, and this comes from Dave Turkaly from Citizens.
2. Question Answer
Charlie, I got -- I think I have a bunch of questions. I want to ask that you may not want to answer, but let me just start off by asking you in terms of the users that you're hitting with the new AYON product, are there non-Renuvion folks? And any people sort of like outside of your core plastic docs?
Yes. So the answer to the first part of the question is yes. We are getting people that have never used Renuvion before that are buying the AYON platform. So that is the first part of your question. And the second part of your question is, for the most part, it's all plastic or cosmetics that are doing, obviously, bodies and seeing these GLP-1 patients coming into their practice. Those are the people who are acquiring AYON right now.
Great. I think we all understand like the footprint difference of having kind of an all-in-one option, but it seems like there's some other benefits. You mentioned Power Lipo, but even with your ultra Lipo and some of the other features that could save the physician's time. So I was wondering if you could just maybe walk us through that quickly.
Yes. It's a good question because what you see from the outside is just the fact that everything is put together in a nice streamlined package, but that really is the least important part of the story. The most important part of the story is that every technology that is in AYON is better than the existing technologies that exist today. And remember, the liposuction that we have for the ultrasonic liposuction, that has been out since we originally launched AYON, but we just got approval for the power-assisted piece in May of this last year.
And the power-assisted piece is a very important part of AYON because that is the part that defines and sculpts the body and actually removes the fat or puts the fat back into other areas, and that is the part that takes the longest in the procedure. So the ultrasonic separates the fat and then the Power Assist comes in and takes the fat out. And then through our closed-loop contouring, you can put it back in.
But let's not forget that in the quarter, we just did a soft launch in the quarter, and we got feedback from the physicians. That feedback was incredibly well received on the Power Lipo product. In fact, it was exceptional. And then we only started to ship to a very few units in June, okay? So we still have work to do as far as building Power Lipo handpieces and getting them out to customers that are still waiting for them.
And the next question comes from Alex Fuhrman from Lucid Capital Markets.
Congratulations on another strong quarter of double-digit growth. I wanted to ask about gross margin. It was up very nicely year-over-year in the first and second quarter this year. It looks like the guidance implies that it's going to come in a little bit sequentially. Can you talk a little bit about what's driving that? It seems like the mix shift to surgical aesthetics has certainly been helping things, and that's expected to continue. So any color on what's driving that change in gross margin would be helpful.
Yes. Look, I don't know that it is too much of a change. There's always a mix in there between international and OUS and U.S. And so I don't know that fundamentally that there's any change. It has overperformed the first 2 quarters, which is obviously very nice. We're very happy with that. But remember, we're in the process of rolling out the Power Lipo right now.
And obviously, the first ones of anything that you make are going to be the most expensive ones, and you're going to see that get better and better as time goes on as manufacturing has more throughput as we get better at making them and all of those things. And so when we're looking at the second half, remember, we're just gearing up on the Power Lipo handpiece. And so there's -- we're looking at that and making sure that we're able to deliver and do the things that we need to do there.
The next question comes from Matthew Hewitt from Craig-Hallum.
This is Tollef Kohrman on for Matt Hewitt. So for Power Lipo, is that at all embedded into the guidance?
When you say embedded into the guidance, yes. I mean, Power Lipo is always something that we had anticipated to have in the back half of the year. And yes, it is in the guidance.
Okay. And then are you guys expecting any tariff refunds this year?
We are in the process of going through that. We would expect to receive some, and we don't really have any idea exactly what that would be at this time. And if we did get any tariff refunds, they are not in the current guidance that is out there now.
And the next question comes from Yi Chen from H.C. Wainwright.
Could you remind us how many AYON systems have been placed since launch? And if a customer purchased the system today, do they -- do you expect all of them to purchase it with the power liposuction attachment?
Yes. So we have not given the number of AYON that are in the market. So I will not be able to give you that number today. But we would expect that the vast majority of people who are buying an AYON would have a power Lipo would have Power Lipo with it. I would say north of 95% of people would have Power Lipo with it.
So adding the power liposuction does increase recurring handpiece revenue, right? Or it just primarily improved the platform's competitiveness?
Well, so both. But remember, the Power Lipo handpiece is and probes are reusable with a useful life. So -- and they're measured in hours. So the handpieces would need to be replaced over time. Typically, a busy practice would go through 2, 3, 4 handpieces a year and then the probes, obviously, with them, too. So they are reusable, but they have a useful life.
Okay. And I don't know if you have some preliminary data you can share with us that for surgeons that purchased the AYON system, what is the average first year or second year recurring consumable revenue?
Yes. So the -- we have talked about the procedure reoccurring revenue. There is obviously the Renuvion handpiece. And then there is about an extra $100 of tubings and canisters per case that would be recurring on the AYON system.
[Operator Instructions] No further questions that came through at this time. I will now turn the call over back to Charlie Goodwin. Please go ahead, sir.
Yes. I'd like to thank everybody for attending the call today. We're very pleased with the momentum in the business this quarter, and we look forward to the full commercial launch of power liposuction in the third quarter as the next step in building our AYON platform. We appreciate all the support we have received from our shareholders during this time, and I can't thank you all enough. Have a good night.
Thank you. This concludes our conference call for today. Thank you all for participating. You may now disconnect.
Apyx Medical Corporation — Q1 2026 Earnings Call
1. Management Discussion
Ladies and gentlemen, good morning, and welcome to Apex Medical First Quarter 2026 Earnings Conference Call. As a reminder, this conference is being recorded.
It is now my pleasure to introduce your host, Jeremy Pepper from LifeSci Advisors. Please go ahead.
Thank you, and welcome, everyone, to our first quarter 2026 earnings call. Representing the company on the call are Charlie Goodwin, Chief Executive Officer; and Matt Hill, Chief Financial Officer of AFIX.
Before we begin, I would like to remind everyone that our remarks and responses to your questions today may contain forward-looking statements that are based on the current expectations of management and involve inherent risks and uncertainties that could cause actual results to differ materially from those indicated, including, without limitation, those identified in the Risk Factors section of our most recent annual report on Form 10-K, our most recent 10-Q filing and the company's other filings with the Securities and Exchange Commission.
Such factors may be updated from time to time in our filings with the SEC, which are available on our website. We undertake no obligation to publicly update or revise our forward-looking statements as a result of new information, future events or otherwise.
This call will also include references to certain financial measures that are not calculated in accordance with generally accepted accounting principles or GAAP. We generally refer to these as non-GAAP financial measures. Reconciliations of those non-GAAP financial measures to the most comparable measures calculated and presented in accordance with GAAP are available in the earnings press release on the Investor Relations portion of our website.
I would now like to turn the call over to Mr. Charlie Goodwin, Apyx Medical's President and Chief Executive Officer. Please go ahead.
Thank you, Jeremy, and thank you all for joining us today. For our usual format on these quarterly calls, I will begin with a review of our performance over the past several months and then turn the call over to Matt for a review of our first quarter 2026 financial results, along with our updated guidance for full year 2026. We will then open the call for your questions.
Let me begin with a review of a few key highlights from our first quarter 2026 performance. We reported total quarterly revenue of $12.5 million compared to $9.4 million in the same period last year. This growth was driven by a 36% increase in sales of our surgical aesthetics products to $10.7 million for the first quarter, which was primarily attributable to the continued strong sales ramp of our Aon body contouring system in the U.S., demand for single-use handpieces worldwide and increase in Renuvion generator sales internationally.
This represents our second full quarter of AAON sales following its full commercial launch in September 2025. Notably, while demand from our existing generator and Renuvion customer base continues to be strong, we are also generating a steady increase in engagement from new accounts, reflecting growing market awareness of AAON and increasing confidence in the breadth of its capabilities. Importantly, we continue to believe adoption remains in the early stages.
Over these past several months, I have been very pleased by how the commercial program for AAON has quickly ramped up activity. Our team has risen to the occasion and executed a disciplined, high-quality launch focused on training and workflow integration to achieve customer success. We are also pleased the release of AON has coincided so well with the continued rapid adoption of GLP-1s.
As of early 2026, roughly 1 in 8 U.S. adults report have taken a GLP-1 according to KFF health tracking polls and RAN reports. While approximately 6% of adults are currently using them, projections indicate that demand will continue to grow with estimates suggesting around 30 million Americans could be using GLP-1 treatments by 2030. The rapid weight loss that occurs using these drugs can lead to significant loose and lax skin that can only be effectively managed using a surgical intervention, and we believe Renuvion and AON are the most advanced and effective method for treating loose and lax skin through body contouring.
In addition to our revenue growth, we remain proud of the lean operating structure we implemented just over a year ago, which has materially reduced our operating expenses and cash burn. Those changes have strengthened our financial position and given us the flexibility to selectively reinvest in high-return growth initiatives, including the continued rollout of AON and our broader surgical aesthetic strategy.
Through the launch of AAON, we have expanded our customer relationships beyond individual technologies to a more comprehensive presence in the surgical suite, supporting a wider range of procedures and workflows. As I have mentioned previously, this is a groundbreaking body contouring offering designed by leading surgeons to address many of the challenges and limitations of existing systems. AAON is differentiated by its ability to integrate multiple core body contouring modalities on a single platform. allowing surgeons to streamline procedures, reduce equipment complexity and support optimal patient outcomes.
As a result, we are seeing strong market receptivity reinforcing our view that AAON is addressing a meaningful unmet need and adoption remains in the early stages. Building on this success and expanding upon the AAON suite of offerings even further, we anticipate FDA 510 clearance for the AON platform to include power liposuction sometime this quarter.
This is a core modality in modern body contouring procedures, and this clearance meaningfully expands AAON's functionality so that it now supports multiple advanced fat removal modalities on one platform. Importantly, we believe this further differentiates AAON in the market and broadens its addressable customer base. When cleared, our strategy for bringing the power liposuction functionality live, our team is implementing a limited commercial launch of power liposuction with highly targeted early adopters.
Over the coming months, this program will serve as a critical proving ground to refine training, optimize utilization and evaluate the end-to-end customer experience. As we did with our AAON system in advance of its full launch, we will take a disciplined approach before scaling commercial implementation. We look forward to sharing further updates on this program as this program progresses.
Looking beyond the U.S., we have tremendous opportunities following key regulatory approvals over just the past few quarters, including Renuvion in Asia. In South Korea, we experienced solid interest around the Apyx One console and single-use handpieces immediately following our regulatory approval in December of 2025.
As a reminder, South Korea represents an attractive market for surgical aesthetics and early customer interest and initial purchase activity reinforce our confidence in the long-term opportunity there. While it is still in the early stages, the initial customer demand for our generators and handpieces exceeded expectations, and we look forward to building on this initial momentum.
To summarize, our long-term vision is simple: to walk into every surgical center and see an AN at the center of the operating room, I believe we are off to an excellent start.
I will now turn the call over to Matt for a review of our first quarter 2026 financial results in more detail, along with our updated financial guidance for 2026.
Thank you, Charlie. Before I get started, please note that all references to our first quarter financial results will be on a GAAP and a year-over-year basis, unless noted otherwise. As Charlie mentioned, total revenue for the first quarter of '26 increased 32% to $12.5 million compared to $9.4 million in the prior year period. Revenue for Surgical Aesthetics segment increased 36% or $2.8 million to $10.7 million compared to $7.9 million for the prior year period.
As Charlie referenced, this growth was driven by sales of AON as we commenced our commercial launch towards the end of the third quarter of 2025, increased sales of generators internationally and increased volume of single-use handpieces in both domestic and international markets. These increases were partially offset by decreases in domestic sales of generators.
Turning to the OEM segment. Sales increased 14% or approximately $0.2 million to $1.8 million for the first quarter of '26 compared to $1.5 million for the first quarter of '25. The increase in OEM sales was due to increases in sales volumes to existing customers, while OEM segment sales increased for the 3-month period with an increased focus on surgical aesthetics, we expect the OEM segment revenue will decrease for the year and that this trend will continue over time.
Domestic revenue increased 20% year-over-year to $8.1 million and international revenue increased 63% year-over-year to $4.4 million for the first quarter of 2026. As a reminder, the medical device industry typically experiences some seasonality with revenue trends generally lowest in the first and the third quarters and strongest in the second and fourth.
Gross profit for the first quarter '26 increased 40% to $7.9 million compared with $5.7 million in the prior year period. Gross profit margin for the first quarter of '26 increased to 63.5% compared to 60.1% in the prior year period. The increase in gross margin for the 3 months ended March 31, 2026, from the prior year period is primarily attributable to mix between our segments with the surgical aesthetics comprising a higher percentage of total sales and product mix within our OEM segment.
This was partially offset by geographic mix with international sales comprising a higher percentage of total sales and tariffs that began affecting us in the second half of 2025. Operating expenses were relatively flat year-over-year with $8.8 million for the first quarter of '26 compared to $8.7 million for the prior year period.
This was due to a combined $0.3 million increase in selling, general and administrative expenses and salaries and related costs, which was offset by a combined $0.2 million decrease in research and development and professional services expenses. Loss from operations was $0.9 million compared with a loss from operations of $3.1 million for the first quarter of 2025.
Net loss attributable to stockholders was $2.1 million or $0.05 per share for the first quarter of '26 compared with $4.2 million or $0.10 per share in the prior year period. Adjusted EBITDA loss was $0.3 million for the first quarter of '26 compared to an adjusted EBITDA loss of $2.4 million in the first quarter of '25.
As a reminder, we provide a detailed reconciliation from net loss attributable to stockholders to non-GAAP adjusted EBITDA loss in our earnings press release. For the 3 months ended March 31, 2026, cash used in operating activities decreased to $0.6 million compared to $0.7 million used in the prior year period. As of March 31, 2026, the company had cash and cash equivalents of $31.1 million.
We believe based on our projections, including the uptake of the AON platform, working capital management and our strict cost controls will yield cash through 2027. Turning to our '26 guidance. For the 12 months ended December 31, 2026, we announced an upward revision to our expected total revenue to be in the range of $59 million to $60 million, up from the previous guidance of $57.5 million to $58.5 million. This is compared with $52.8 million reported for the year ended December 31, 2025.
Our revenue guidance assumes Surgical Aesthetics segment revenue in the range of $54 million to $55 million, up from the previous guidance of $53 million to $54 million. This is compared with approximately $45.3 million reported for the year ended December 31, 2025. OEM revenue is now expected to be approximately $5 million, up from the previous guidance of $4.5 million.
This is compared with approximately $7.5 million for the year ended December 31, 2025. We now, depending on product and geographic mix, anticipate gross margins of approximately 62% to 63% for the year and total operating expenses not to exceed $45 million.
This completes our prepared remarks. Shelley and I will now open the call for questions.
Your first question comes from David Perklich from Citizens.
2. Question Answer
Congrats on the quarter and the guide. Charlie, just upfront really quick. I heard Matt say the U.S. generator sale decrease. And I noticed in the press release, you kind of pulled out a comment that said ION was not part of the sale. I just want to be clear because it seems like everything was really strong. Can you explain that detail that's there, like exactly what you're saying in the press release?
Yes. Yes, it's a good question, Dave. Basically, when we're selling AOs now, we're counting those as AN sales and not generator sales, even though if they're a brand-new customer, they would have a generator with them or if they're an RS 3 upgrade, they would need to upgrade to the Apyx One. We don't capture those generators separately. We count it all as an Aon sale now. So more than anything else, it's just the geography. You're going to see that in the U.S. as we continue more people are going to buy full Aon systems as opposed to just buying generators as they were before.
And then as we look -- obviously, OUS was really strong. You called out South Korea. Will you bring AN there? I think Apyx One is there right now, but is that the plan? And any color on sort of OUS rollout with that system?
Yes. If you look at the international business, it was a good, obviously, quarter for the international business. And as Matt and I both said, it was strength on handpieces, both from an international and a domestic perspective, but new generator sales and new upticks in South Korea, in particular, for outside the United States. And yes, we are working on registering AON outside the United States, obviously.
And so we will be working on various countries throughout this year. And as we make progress on that, we will obviously let the investors know of what we're doing there. But yes, we plan to have AAON registered everywhere in the world at some point in time.
Next question comes from Sam Eiber from BTIG.
Charlie, maybe a 2-part question on AN. First, maybe I can get your thoughts on where you think we are in this rollout in the launch. It sounds like maybe you're starting to expand beyond the existing group of Renuvion accounts. And then just as a follow-up there on power assisted liposuction, nice to hear that you're expecting label expansion this quarter. Has that been an impediment at all toward adoption? And with the label, could we expect some inflection thereafter? And how important is that going to be for surgeons?
Yes. No, it's a good question, and there's a lot in there. I'll try to unpack it for you. It's a multi-tiered question for sure. When we're talking about the existing Renuvion customers upgrading to AN, we've actually just started with that. So that is a whole huge group of people that we have that could upgrade to Aon. And then obviously, to your point, it brings in a whole bunch of people that don't even have Renuvion at this time that could upgrade to that.
And so we are -- if we're looking at AN sales in the United States, and this is a baseball game, we're just in the top of the first inning. We're just basically getting started with this. As regards to power lipo, yes, to answer your question directly, there are people that are waiting for power lipo before they get Aon because some doctors do not use ultrasonic liposuction. They only use power liposuction.
So if you look at the market, you've got groups of doctors that use both ultrasonic and power. You've got doctors that use ultrasonic by itself and not power. And then you've got doctors that use power liposuction and not ultrasonic. And obviously, the doctors that use only power liposuction are waiting for that label and that product to be available before they would get AON.
So from our perspective, power lipo is a huge indication for us and a huge approval because it rounds out the liposuction capabilities of AON that give doctors both modalities on the system as it is today. So we do see it as being very significant.
Okay. That's really helpful. Maybe I can just use my follow-up here on the demand environment. It sounds like consumables globally were up in the quarter. you guys have this tailwind with the GLP-1 wave that's coming in. But obviously, I know there's some geopolitical tensions, macroeconomic dynamics in the current environment. Just curious what you're seeing out in the field for underlying procedure demand at this moment.
Yes. I don't think there's any question that people that have been on these drugs and have lost the weight that they want to lose are looking for solutions to help their body. And yes, there is a lot of noise out there on the geopolitical front. There's no question about that. But from a demand perspective, we're still seeing patients coming into practices and wanting these procedures.
Next question comes from Alex Fuhrman from Lucid Capital Markets.
Congratulations on a really strong start to the year. It sounds like most of the AAON customers have been skewing towards new customers if you're only just starting to sell as an upgrade to your long-standing customers. Curious, Charlie, what kinds of clinics has it been resonating the most with? And are there practices that you had a hard time getting into when it was just Renuvion that are now taking another look with the full all-in-one?
Yes. So I actually want to just clarify one thing. So far, all the Aons that we've sold, probably about 80% of them have been to Renuvion -- existing Renuvion customers. But if you look at the total base of Renuvion customers, we still have a long ways to go before we upgrade all of them, okay?
And to answer your question about the new customers that weren't Renuvion customers before or APyx customers before, to answer your question, yes, it is a huge help having Aon because now you're talking about the entire body contouring procedure. You're talking about adding technologies that increase efficiency for the doctor and their staff lower patient -- lower procedure times for the patient, which is huge because they're less time under anesthesia. And we're even being told anecdotally from doctors that the outcomes are better for the patient. So yes, it is helping us immensely get into practices that we weren't in before for sure.
Okay. That's really helpful. And then you referenced a study earlier in the call that suggested about 1 in 8 Americans have taken a GLP-1. Obviously, your business is doing very well here at a time when GLP-1 adoption is growing. Do you have any sense just kind of anecdotally, customers having a Renuvion treatment? I mean, do you feel like there's more than 1 in 8 or about that share that have taken a GLP-1? Just curious if that's been kind of a driver of the business or what you're hearing from your surgeons?
Yes. And we follow like Google searches and things like that, too, about what consumers are looking for and what they're seeing. And if you take a look at Google searches and you go over the last 12 months, one of the biggest increases is on loose skin. And so yes, we are seeing patients that are coming to the doctors' practices and they're asking for solutions for that.
And it is -- if you look at, I think, the 3 biggest things in Google searches that are looking for right now, it's loose skin, body contouring and liposuction still. So people are looking for these solutions. They're taking these drugs. They're losing the weight. And obviously, they've got loose and la skin after that. So we are seeing this in the marketplace. And I think that's that's why we're seeing the strength that we're seeing and the growth that we're having is because we think that the technologies and solutions that we're helping doctors with are squarely in the sights of what the patients are looking for.
Next question would be from Matt Hewitt from Craig-Hallum.
This is Tollef Kohrman on for Matt Hewitt. Congrats on a great quarter. So what's the assumed tariff impact embedded in the guide? And how should we think about any potential changes in the policy going forward?
Yes. Look, I don't know about changes in the guide. We're anticipating that the tariffs are going to remain throughout the rest of the year, and they're factored in there from, obviously, a cost and a gross profit point of view. So I mean, could things change and we have different tariffs? Absolutely. But one of the advantages that we have is that we manufacture both in Sofia, Bulgaria and Clearwater, Florida. And so we've been able to minimize the tariff impact so far to the business. But it is something that we're always looking at and finding the best way to keep our costs as low as they possibly can be.
Excellent. And then earlier in the call, you cited you wanted to place AN outside of the U.S., specifically everywhere. Just can you give a time line in key specific countries you're looking at right now?
So I can't give a time line, unfortunately, because I would -- anything I would give you would be wrong because it takes time in each individual country. But obviously, there's major places that we'd like to have AAON registered from a body contouring perspective. Obviously, all of Europe, we'd like to have it there. When we're looking at Latin America, we'd be looking at countries like Brazil and Colombia that do a lot of body contouring. We'd obviously be looking at the Middle East because there's a lot of business there and then key markets in Asia. So those would be the big areas that we'd be looking for AON.
Ladies and gentlemen, this concludes our question-and-answer session. I would now hand the conference over to Charlie Goodwin for his closing comments.
Thank you, everybody, for attending the call. I want to really thank the entire Apyx Medical team for their tireless dedication and execution as we move into mid-2026 with tremendous energy and momentum towards driving growth. We appreciate all the support we have received from our customers and shareholders during this time. Thank you very much.
Thank you. The conference of Apyx Medical has concluded. Thank you for your participation. You may now disconnect your line.
Apyx Medical Corporation — Q4 2025 Earnings Call
1. Management Discussion
Good morning, ladies and gentlemen, and welcome to the Apyx Medical Fourth Quarter and Full Year 2025 Earnings Conference Call. [Operator Instructions]
I would now like to turn the conference call over to Jeremy Feffer, LifeSci Advisors. Please go ahead.
Thank you, and welcome, everyone, to our fourth quarter and full year 2025 earnings call. Representing the company on the call are Charlie Goodwin, Chief Executive Officer; and Matt Hill, Chief Financial Officer of Apyx. Before we begin, I would like to remind everyone that our remarks and responses to your questions today may contain forward-looking statements that are based on the current expectations of management and involve inherent risks and uncertainties that could cause actual results to differ materially from those indicated, including, without limitation, those identified in the Risk Factors section of our most recent annual report on Form 10-K, our most recent 10-Q filing and the company's other filings with the Securities and Exchange Commission. Such factors may be updated from time to time in our filings with the SEC, which are available on our website. We undertake no obligation to publicly update or revise our forward-looking statements as a result of new information, future events or otherwise.
This call will also include references to certain financial measures that are not calculated in accordance with generally accepted accounting principles or GAAP. We generally refer to these as non-GAAP financial measures. Reconciliations of these non-GAAP financial measures to the most comparable measures calculated and presented in accordance with GAAP are available in the earnings press release on the Investor Relations portion of our website.
I would now like to turn the call over to Mr. Charlie Goodwin, Apyx Medical's President and Chief Executive Officer.
Please go ahead.
Thank you, Jeremy, and thank you all for joining us today. Per our usual format on these quarterly calls, I will begin with a review of our performance over the past several months and then turn the call over to Matt for a review of our fourth quarter and full year 2025 financial results, along with our guidance for full year 2026. We will then open the call for your questions. Let me begin with a review of a few key highlights from our fourth quarter and full year 2025 performance. We reported a record revenue of $19.2 million compared to $14.2 million in the same period last year. This growth was driven by a 38% increase in sales of our surgical aesthetics products to $16.7 million for the fourth quarter, which was primarily attributable to sales of our AYON body contouring system. As many of you are aware, the fourth quarter represents the first full quarter of AYON sales following its full commercial launch in September of '25.
As a result, this is a very telling moment for us as a company as we begin to see the market excitement we have discussed over the past several quarters meaningfully reflected in our financial results. Looking back since unveiling AYON approximately one year ago when it was submitted for FDA clearance, we have seen a steady and consistent rise in market interest. Following market clearance in May of 2025, we initiated a soft launch that generated overwhelmingly positive feedback from the early adopters, and it quickly became clear to our team that this system was special and positioned us to have significant impact on the future of aesthetic surgery market. I am excited to report that this positive feedback has translated into strong market demand and sales following full launch, and we continue to ramp our operations to meet this demand. As I have mentioned previously, our team was well prepared for the full commercial launch, including strong preorders generated during soft launch.
To date, the launch of AYON and the level of incoming interest from customers submitting orders has exceeded our expectations across every metric. As we look at the market's reaction to AYON, it is clear that the reception aligns with what this technology is designed to deliver, and we believe its adoption curve is still in the very early stages. AYON is a groundbreaking body contouring system designed by leading surgeons to address many of the challenges and limitations of existing systems. Unlike most systems on the market, which are limited to single function, AYON seamlessly integrates fat removal, closed-loop contouring, tissue contraction and electrosurgical capabilities, empowering surgeons to deliver the most comprehensive body contouring treatments available. With advanced features such as LIFT Technology for real-time adjustments and Renuvion for enhanced tissue contraction, AYON sets a new standard in surgical care by streamlining procedures and maximizing patient outcomes.
The result is a system that combines precision, versatility and innovation in an all-in-one platform, offering surgeons an unmatched return on investment. Importantly, the plastic surgery market has not seen a device with this level of advancement in many years. When we first introduced AYON and talked about the initial capabilities, we also committed to submitting a follow-up 510(k) for label expansion to include power liposuction. During the fourth quarter, our team submitted this follow-up application. Since then, we have engaged in productive discussions with the FDA. And based on this progress, we now anticipate receiving market clearance in mid-2026. Achieving market clearance for power liposuction will further strengthen AYON's position as the first fully integrated body contouring system, positioning it as the new gold standard in surgical aesthetics. Importantly, upon receiving clearance, we will be able to activate this function on systems already in the field. We will also be able to launch our power-assisted liposuction handpieces and continue to expand our revenue.
With these continued enhancements to the platform and the strong feedback we are receiving from surgeons, AYON is well positioned to capitalize on the broader shifts occurring in the aesthetics market. At the same time, the market itself continues to evolve. Over the past year, we have seen the space begin to emerge from a period of softer demand and that renewed momentum we are seeing today looks very different from what drove the market just 5 years ago. As I have said on previous calls, one of the biggest new drivers of this shift is the rapid adoption of GLP-1 drugs for weight loss. A growing number of these patients are experiencing skin laxity after significant weight loss and after patients achieve their weight loss goals, we believe they will be seeking treatments for the resulting loose and lax skin. This is where GLP-1 headwinds turn into tailwinds for companies uniquely positioned to provide the tools for those treatments like Apyx Medical.
Our Renuvion system, which is available as both a stand-alone offering and an integrated component of AYON has proven to be an exceptional treatment option for this type of skin laxity. We believe Renuvion is best-in-class and should be considered the new standard of care, particularly for patients experiencing loose or lax skin after rapid weight loss. With more than 15 million people currently on GLP-1 drugs in the U.S. alone, we believe we are still in the early innings of a powerful market shift. Apyx is uniquely positioned to help meet this demand and lead the aesthetics market into the next phase of growth. I will close this thought by highlighting that the shift in patient results as well as the financial resources they are putting towards treatments being driven by the widespread adoption of GLP-1 drugs are unlike anything the weight loss and plastic surgery markets have experienced in recent history.
This shift represents a tremendous opportunity, and we are very fortunate to already have a solution in our portfolio that delivers best-in-class durable outcomes for these patients. As we look to take full advantage of this momentum behind our business, we are actively strengthening our commercial organization by acquiring high-caliber sales talent aligned with our next phase of growth. These new team members are expected to increase our ability to build market share as well as deepen our ability to support surgeons through training, onboarding and practice development, which we know are critical to accelerating market adoption. To be clear, these investments will be measured and aligned with our growth trajectory of our business. As a reminder, it is just over a year ago that we successfully implemented significant cost reduction and restructuring, and we have no plans to reverse the progress achieved through that effort. We are proud of the restructuring efforts that have resulted in leaner operating structure and meaningfully reduced our cash burn.
These improvements strengthened our overall financial health, giving us the flexibility to invest in AYON and our broader growth strategy with confidence. It is encouraging to reflect on the positive outcome driven by our team's dedication and perseverance. I will close my comments by saying how pleased I am by the progress we have made over these past several months since the launch in September. We believe we have just scratched the surface of the overall market for AYON, and we look forward to realizing our long-term vision of walking into almost every surgical practice and seeing an AYON system at the center of the operating room.
I will now turn the call over to Matt to review our fourth quarter and full year 2025 results in more detail, along with our financial guidance for 2026.
Thank you, Charlie.
Before I get started, please note all references to fourth quarter and full year financial results will be on a GAAP and year-over-year basis, unless noted otherwise. As Charlie mentioned, total revenue for the fourth quarter '25 increased 35% to $19.2 million compared to $14.2 million in the prior year period. Revenue for the Surgical Aesthetics segment increased 38% or $4.6 million to $16.7 million compared to $12.1 million for the prior year period. As Charlie referenced, this growth was driven by sales of AYON as the company commenced its commercial launch in September and increased volume of single-use handpieces in both domestic and international markets. These increases were partially offset by decreases in domestic sales of generators, including upgrades to the Apyx One Console, where the purchase of AYON was not part of the net sale and upgrades to the Apyx One Console in international markets.
Overall, Surgical Aesthetics sales domestically increased by nearly 50% from the prior year period. Turning to the OEM segment, sales increased 16% or approximately $0.3 million to $2.5 million for the fourth quarter of '25 compared to $2.1 million for the fourth quarter of '24. The increase in OEM sales was due to an increase in sales volume to existing customers, including Symmetry Surgical under our 10-year generator manufacturing and supply agreement. Domestic revenue increased 42% year-over-year to $15 million and international revenue increased 15% year-over-year to $4.2 million. As a reminder, the medical device industry typically experienced some seasonality with revenue trends generally lowest in the first and third quarters and strongest in the second and fourth. Gross profit for the fourth quarter '25 increased to $12 million compared with $9 million in the prior year period.
Gross profit margin for the fourth quarter '25 decreased to 62.6% compared to 63% in the prior year period. Operating expenses were flat year-over-year at $12 million for the fourth quarter '25 as well as the prior year period. There were certain shifts in the underlying expenses with $0.2 million decreases for selling, general and administrative expenses and research and development expenses, which were offset by $0.2 million increases in salaries and related costs and professional service expenses. Income from operations was $11,000 compared with a loss from operations of $3 million in the fourth quarter of '25. Net loss attributable to stockholders was $1.3 million or $0.03 per share for the fourth quarter of '25 compared with $4.6 million or $0.12 per share in the prior year period. Adjusted EBITDA was $0.7 million compared to an adjusted EBITDA loss of $2.2 million in the fourth quarter of '24. As a reminder, we provide a detailed reconciliation from net loss attributable to stockholders to non-GAAP adjusted EBITDA loss in our earnings press release.
For the 3 months ended December 31, 2025, cash used in operating activities decreased to $2.5 million compared with $2.9 million used in the prior year period. For the year ended December 31, 2025, cash used in operating activities decreased to $8 million compared to $18.7 million used in the prior year period. We were pleased with the cash and working capital management in the full year 2025 with cash burn returning to a lower but more normalized rate in the back half of the year as a result of the impact of changes in working capital as a result of AYON's launch. As of December 31, 2025 and 2024, the company had cash and cash equivalents of $31.7 million. We believe based on our projections, including the uptake of the AYON platform, working capital management and our continued strict cost controls, we will yield cash through 2027.
Turning to our 2026 guidance. For the 12 months ended December 31, 2026, we expect total revenue in the range of $57.5 million to $58.5 million. This reflects approximately a 9% to 11% increase as compared to the full year of 2025. This is the result of an increase in sales in our Surgical Aesthetics segment and a decrease in sales in our OEM segment. Our revenue guidance assumes Surgical Aesthetics segment revenue in the range of $53 million to $54 million. This reflects a 17% to 19% increase compared to 2025 OEM revenue is expected to come in at approximately $4.5 million as compared to $7.5 million for 2025. This decrease continues to reflect our decision to focus our resources on the Surgical Aesthetics segment. We now anticipate gross margins of approximately 61% to 62% for the year and total operating expenses not to exceed $45 million. As Charlie mentioned, we are pleased to see the result of our cost-cutting measures taken in the fourth quarter of 2024 in our current numbers. We believe the company performance in 2025 reflects the great team we have here at Apyx.
To summarize, in just one year, this team submitted for and received FDA clearance and subsequently launched a groundbreaking new product into a space with significant headwinds. Despite that backdrop, we delivered 10% overall sales growth and 17% growth in Surgical Aesthetics, achieving record sales in the fourth quarter. And we accomplished this while simultaneously reducing operating expenses to $39.5 million, down from $48.2 million in 2024 and $53.7 million in 2023. As a result, we are excited to report positive EBITDA in the fourth quarter. Now we are projecting continued growth into 2026 as we continue to manage our expenses. It is indeed an exciting time here for Apyx.
This completes our prepared remarks. Charlie and I will now open the call for questions.
Operator?
[Operator Instructions] Your first question is from Dave Turkaly from Citizens.
2. Question Answer
Congrats. Charlie, I think I heard some commentary about a handpiece and CapEx sales, but I was wondering if we might be able to get a little more color maybe just even domestically. Obviously, we know the aesthetic growth rate in the quarter. But I was wondering if you could maybe give us color, I would imagine maybe capital is growing faster given AYON, but -- could you comment on directionally, which is growing faster and then maybe if CapEx is seeing a price uptick?
When you say CapEx, do you mean handpieces? What do you mean by CapEx?
Capital, capital equipment. Just -- system sales.
Yes. Look, our growth in the fourth quarter was definitely driven by AYON, and that was our focus as a company. It was our focus as a sales team, especially in the United States was driving AYON systems. The whole organization was working hard to produce systems, and we were selling systems. And obviously, that was the driver of growth in the fourth quarter for us. Domestically, we grew almost 50% in the U.S., and I think it was 38% as a total company. And so it was on the back of AYON. It was on the back of this revolutionary platform for sure.
And I guess just as a follow-up, any pricing commentary that you give on that? I think you're able to sell that given the components at a higher price. But also sort of looking for maybe some commentary around new customers. Are you seeing is it mostly repeat folks that are upgrading to AYON that you know? Or is it -- any color on how many new customers are interested in the system?
Yes. So it is a combination of both. It is a combination of people who already have the Renuvion platform, whether it be an Apyx One generator or an RS3 generator that would upgrade to AYON. And that was, I would say, probably about 80% of our sales in the fourth quarter, but there were still about 20% of new customers that were both new to the Renuvion platform and obviously, the AYON platform. that purchased AYON. And so we're seeing a nice mix of both for sure, and we would expect that to continue. As far as pricing goes, we haven't actually talked about the specific pricing other than the list price of AYON is about $360,000, and that is simply the list price of the Apyx One generator, plus all the competitors' components that make up AYON.
And remember, we've said that we're able to bring it to the market at a much greater value buying it together than all the separate pieces. So there is a value proposition for the doctors to get an integrated system, along with the benefits that they get from the technologies that are in AYON and along with the benefits that they and their staff get from a workflow benefit of AYON.
Your next question is from Sam Eiber from BTIG.
Congrats on a nice finish to the year. Charlie, sitting here, I guess, 6 months into the AYON launch, I guess, what's been going well? What's going better than expectations? What are some things that maybe you have to fine-tune? Would just love any updates on, I guess, what you're hearing from customers and then from the commercial reps out in the field?
Yes. No, it's a great question. And the great news is it's all good news. The customers love AYON. The one thing that they would like to have with AYON is the power-assisted handpiece, which we expect that definitely here in the first half of the year because that completes the liposuction portion of AYON. And so there is no question that there are a lot of people that want the power-assisted portion. But the feedback from AYON itself has exceeded every expectation that we have had. The launch has gone incredibly well. Sure, there's been a couple of minor hiccups along the way, but the team has done an incredible job of dealing with those and making sure that everybody is happy with the system. And like we said in the prepared remarks that every metric that we had has been there and then some with AYON.
And remember, there is nothing like this system in the marketplace today. And so really haven't ran into a single surgeon that hasn't thought it's a great idea, hasn't really liked it and is going to consider how to bring this into their practice. And so we are just getting started. When you said 6 months, it's been 6 months since we basically got approval. But remember, we didn't start shipping the product until September. And like I said, we're still waiting on the power-assisted handpiece to get that into the hands of the doctors to complete the liposuction offering for AYON.
Yes. Very good. And maybe just a quick follow-up for Matt. I guess just thinking about the gross margin guidance, relative to 2025. Is it fair to think of that maybe is a little conservative considering the mix coming from OEM is going to be a little bit lighter next year? Just love to hear the puts and takes to the gross margin guidance.
Sam, great question. Yes, any time we're giving guidance, we're trying to be as conservative as possible. It will depend on -- the levers are the lower margins coming out of OEM as compared to the higher margins coming out of the Surgical Aesthetics segments, offset by sales mix geographically. So if we have higher sales in China, full year sales in China in 2026 as well. So there will be some geographic mix.
Your next question is from Alex Fuhrman from Lucid Capital Markets.
Congratulations on the strong AYON launch and a strong year in 2025. I wanted to ask about the new salespeople that you're adding. Can you talk a little bit about how you're dividing territory and incentivizing the sales force? And where do you see the most opportunity to leverage these new hires?
Yes. No, I appreciate the question. So as far as territories go, what we've done is we've just made some change in basically with some of the people that we have had. The nice thing with AYON is it definitely puts us in a position of strength as a company to go out and get some of the top talent in the industry. And obviously, we brought John Featherstone in to help us with that. And for the -- if you look at the aesthetics industry and especially the surgical side of aesthetics, I don't know if there's a more exciting product or platform than AYON to be selling in the marketplace today. And so it really does put us in a strength as a company. We are no longer just a one technology company, but we've got a whole suite of offerings for body contouring.
And quite frankly, as we talked in the prepared remarks, with the change in the patient population and with the adoption of the GLP-1 drugs and the weight loss associated with that and the loose and lax skin as a result of that, body contouring becomes a huge part of the doctor's practice. And we think that AYON and Renuvion are uniquely positioned to help them with the tools to be able to take care of these patients. And so from our perspective, it's a perfect time to be out there getting the absolute best sales talent in the industry to execute this and to drive it for many years to come.
And your next question is from Matt Hewitt from Craig-Hallum.
This is Tollef Kohrman on for Matt Hewitt. Can you remind us what countries AYON is approved in? And what your plans are for further expansion there?
You asked about AYON specifically, correct?
Yes.
Yes. So right now, it's just the United States. There are a couple of countries outside the United States that take FDA. And obviously, it would be registered in there. There's a couple in the Middle East. and the Caribbean, believe it or not. But other than that, we're still -- we still will this year be trying to register it in a lot of key countries outside the United States with obviously Europe, Brazil and Colombia being high on that list. So as we've talked about before, we are just getting started with this. And obviously, we've got a lot of areas throughout the world to get this registered and to get it sold in.
Awesome. And then with the liposuction label expansion now expected midyear, did you incorporate any contribution this year? Or does that represent upside?
We typically do not forecast, if you will, for stuff that we don't have. So obviously, we will still be selling AYON consoles and those consoles were obviously implied in the guidance, if you will. But the handpieces itself, those will be on an upside basis.
Your next question is from Kyle Bauser from ROTH Capital Partners.
Maybe just on console sales. So obviously, AYON was a very big reason for the strong results to the end of the year last year. Just curious, going forward, are the majority of console sales AYON? Or are they still Renuvion? Just trying to get a sense of what that mix is or what you anticipated.
Yes. So we actually still sell Renuvion only even in the United States where we have AYON. So if somebody just wants to acquire the skin tightening portions for their practice, we will obviously sell them stand-alone Renuvion. And obviously, outside the United States, we don't have AYON registered, and so we are selling stand-alone Renuvion outside the United States. And so we will always have both available to the marketplace because it's such an important part, especially to treat these new patients, the Renuvion handpiece. But as far as mix goes, in the U.S., I would imagine that more and more people will be acquiring Renuvion through AYON, if I had to guess. But outside the United States, it's obviously right now just Renuvion only.
Okay. Got it. That's helpful. And then, Matt, in your prepared remarks, sorry if I missed it, you mentioned something about 2027. I believe it was about being cash flow positive. Correct me if I'm wrong, just -- and related to that, what are some assumptions that we'll want to keep an eye on in order to kind of achieve reaching cash flow generation?
Great question, Kyle. So from a perspective of cash flow, what we said is that we would have -- we would have cash through 2027, but the plan is that we would be cash flow positive no later than the fourth quarter of 2026.
There are no further questions at this time. I will now hand the call back over to Charlie Goodwin for the closing remarks.
Thank you, everybody, for attending the call. I want to thank the entire Apyx Medical team for their dedication and tireless execution throughout 2025 and as we enter what is expected to be an exciting period of growth for 2026 as we see our plan turn into reality. We appreciate all the support we have received from our shareholders during this time, and thank you all for attending today's call. Thank you.
Thank you. Ladies and gentlemen, the conference has now ended. Thank you all for joining. You may all disconnect your lines.
Apyx Medical Corporation — Q3 2025 Earnings Call
1. Management Discussion
Good morning, ladies and gentlemen, and welcome to the Apyx Medical Third Quarter 2025 Earnings Conference Call. [Operator Instructions] This call is being recorded on Thursday, November 6, 2025.
I would now like to turn the conference over to Jeremy Feffer, LifeSci Advisor. Please go ahead, sir.
Thank you, and welcome, everyone, to our third quarter 2025 earnings call. Representing the company on the call are Charlie Goodwin, Chief Executive Officer; and Matt Hill, Chief Financial Officer of Apyx.
Before we begin, I would like to remind everyone that our remarks and responses to your questions today may contain forward-looking statements that are based on the current expectations of management and involve inherent risks and uncertainties that could cause actual results to differ materially from those indicated, including, without limitation, those identified in the Risk Factors section of our most recent annual report on Form 10-K, our most recent 10-Q filing and the company's other filings with the Securities and Exchange Commission.
Such factors may be updated from time to time in our filings with the SEC, which are available on our website. We undertake no obligation to publicly update or revise our forward-looking statements as a result of new information, future events or otherwise.
This call will also include references to certain financial measures that are not calculated in accordance with generally accepted accounting principles or GAAP. We generally refer to these as non-GAAP financial measures. Reconciliations of those non-GAAP financial measures to the most comparable measures calculated and presented in accordance with GAAP are available in the earnings press release on the Investor Relations portion of our website.
I would now like to turn the call over to Mr. Charlie Goodwin, Apyx Medical's President and Chief Executive Officer. Please go ahead.
Thank you, Jeremy, and thank you all for joining us today. For our usual format on these quarterly calls, I will start with a review of our performance over the past several months, and then I will turn the call over to Matt for a review of our third quarter financial results as well as our updated full year 2025 guidance. We will then open the call for your questions.
But before I jump into the numbers, I'm excited to share an important update about the evolution of our company and our continued commitment to innovation and meaningful outcomes for our customers and their patients. With the development, clearance and launch of the AYON Body Contouring System, one thing has become clear, our identity and the way we present this segment of our business must evolve to reflect who we are today and where we are going tomorrow. That is why we are officially announcing the rebranding of our Advanced Energy segment, which will now be identified as Surgical Aesthetics. This is not just about a new name, it's about better aligning our brand with our mission and the durable and transformational results that our surgical products deliver.
Let me begin with a review of our third quarter performance. We reported total revenue of $12.9 million, compared to $11.5 million in the same period last year. This growth was driven by a $1.8 million increase in sales of our Surgical Aesthetics products to $11.1 million for the third quarter. This is the result of an increase in U.S. sales of over 30% for the quarter and reflects initial sales from our commercial launch of our AYON Body Contouring System during the quarter as well as increased volume of single-use handpieces in both domestic and international markets.
Overall, the AYON soft launch, which took place throughout much of the summer and the full commercial launch in September have been overwhelmingly successful. We are thrilled with the market feedback we're receiving, which has translated in both presales and now initial deliveries, which I will get into more in a moment. I want to note that this growth was offset slightly by a decline in our OEM revenue.
For the third quarter, we reported $1.8 million, down from $2.2 million in the same period last year. This decline was anticipated and is due to reduced sales volumes to existing customers, including Symmetry Surgical under our 10-year generator manufacturing and supply agreement. Strategically, we have shifted our focus and manufacturing resource from OEM towards our Surgical Aesthetics segment, particularly the AYON launch as we believe this segment represents the future of the company.
It is worth highlighting that we made this tremendous progress while emerging from the significant cost reduction and restructuring announced in November 2024. I am proud to share that these efforts have resulted in a leaner operating structure and a meaningful reduction in our cash burn. These improvements have strengthened our overall financial health, giving us the flexibility to invest in AYON and our broader growth strategy with greater confidence.
While restructurings are always challenging, I want to express my sincere gratitude to the employees here at Apyx. It is encouraging to reflect on the positive outcome driven by our team's dedication and perseverance.
Let me now provide a more detailed overview of our progress. It is amazing to think that only about 6 months ago, we received FDA clearance for the AYON system and soon after began to realize the significant impact this system could have on the market. For those who may not be fully up to date, let me provide a brief overview of AYON and why it's generating such a strong market response and why we believe it will help shape the future of aesthetic surgery.
AYON is a groundbreaking body contouring system designed by leading surgeons to address many of the challenges and limitations they experience with current systems in the market. And please keep in mind that most existing systems on the market are limited to a single function while AYON seamlessly integrates fat removal, closed-loop contouring, tissue contraction and electrosurgical capabilities, empowering surgeons to deliver the most comprehensive body contouring treatments available. With advanced features like LIFT technology for real-time adjustments and Renuvion for enhanced tissue contraction, AYON sets a new standard in surgical care, streamlining procedures and maximizing patient outcomes. The result is a system that combines precision, versatility and innovation in an all-in-one platform with unmatched return on investment.
And don't just take our word for it. As part of our soft launch, we initiated an ambassador program with key opinion leaders in critical geographies throughout the U.S. Many of these leading surgeons are now actively discussing how AYON delivers consistent and reliable performance with several of them contributing at our workshops and clinical symposia supporting the broader commercial launch. The feedback has been incredible from the start, which we attribute to the system really filling a void in the market that nothing else has come close to addressing.
Just last month, we hosted a virtual KOL event for investors and analysts featuring comments from world-renowned general and plastic surgeon, Dr. Paul Vanek. We were fortunate to have Dr. Vanek share several case studies using the AYON system, followed by his general insights on the system's functionality and its potential impact on surgical practices. I encourage any of you that missed this event to visit our events page on our company website to listen to the replay, which is just a very compelling overview of the AYON capabilities.
One of the key points raised during the KOL event was the importance of AYON's integration with Renuvion. Our innovative, minimally invasive surgical solution for treating loose and lax skin. Renuvion provides durable transformational outcomes and is rapidly gaining traction among surgeons. We believe it represents the best-in-class option for treating loose skin and should be considered the new standard of care, particularly for patients experiencing skin laxity after significant weight loss, including those using GLP-1 medications.
This expanding patient population presents a tremendous opportunity. With more than 15 million people currently on GLP-1 drugs in the U.S. alone, we're still in the early innings of this powerful market shift. We believe Apyx is uniquely positioned to meet this demand and help lead aesthetic market into the next phase of growth.
As I have said before, the major shifts in the market with the rapid adoption of GLP-1s are unlike anything that we have seen in recent history, and Renuvion has proven to be an exceptional treatment option for the skin laxity experienced by many of these patients. Combined with AYON's other features, we believe Apyx is further differentiated and has elevated our position in the surgical aesthetics market, thereby making us the trusted surgical partner in the next era of aesthetic care.
As I mentioned earlier, the full U.S. launch of AYON began in September and has been highly successful to date. Our team was well positioned following the soft launch earlier this summer and strong interest quickly translated into preorders ahead of the launch. I believe the launch and overall interest in AYON has exceeded all of my expectations across every metric. I look forward to realizing our long-term vision of walking into almost every surgical practice and seeing an AYON system at the center of the operating room.
When we first introduced the AYON and talked about the initial capabilities, one of the commitments we made was the submission of an additional 510(k) to the FDA for the label expansion of AYON to include power liposuction. I am pleased that early last month, our team submitted this follow-up application and anticipate receiving clearance in Q1 of '26. This is an important update as receiving market clearance for power liposuction will solidify AYON's position as the first fully integrated body contouring system, positioning AYON as the new gold standard in surgical aesthetics. I think it is important to note that upon receiving clearance from the FDA, we will be able to activate this function on AYON systems already in the field.
While we are still in the early stages of the launch, the market excitement is quickly turning into orders for AYON. As a result, we are updating our revenue targets for 2025, which Matt will detail in a moment.
I will now turn the call over to Matt for a review of the third quarter 2025 financial results in more detail, along with our updated financial guidance for 2025.
Thank you, Charlie. Before I get started, please note that all references to third quarter financial results will be on a GAAP and a year-over-year basis unless noted otherwise.
As Charlie mentioned, total revenue for the third quarter '25, increased 12% to $12.9 million, compared to $11.5 million in the prior year period. Revenue for Surgical Aesthetics segment increased 19% or $1.8 million to $11.1 million compared to the $9.3 million last year. As Charlie referenced, this growth was driven by sales of AYON as we commenced our commercial launch during the quarter and an increased volume of single-use handpieces in both domestic and international markets. These increases were partially offset by decreases in domestic sales of generators, including upgrades to the Apyx One console, where the purchase of AYON was not part of the sale and upgrades to the Apyx One console in international markets.
Turning to the OEM segment. Sales decreased 18% or approximately $0.4 million to $1.8 million for the third quarter of '25, compared to $2.2 million for the third quarter of '24. The decrease in OEM sales was due to a decrease in the sales volume to existing customers, including Symmetry Surgical under our 10-year generator manufacturing and supply agreement. Domestic revenue increased 20% year-over-year to $9.3 million, and international revenue decreased 4% year-over-year to $3.5 million. As a reminder, the medical device industry typically experienced some seasonality with revenue trends generally the lowest in the first and third quarters and strongest in the second and fourth.
Gross profit for the third quarter '25 increased to $8.3 million, compared with $7 million in the prior year period. Gross profit margin for the third quarter '25, increased to 64.4%, compared to 60.5% in the prior year period.
With respect to tariffs, we continue to monitor trade policy and tariff announcements, including the recent executive orders issued by the U.S. Federal Administration regarding tariffs on imports from various countries. At this time, the overall impact on our business related to these or any other tariffs that may be imposed remains uncertain and depends on multiple factors.
Operating expenses decreased to $9.1 million for the third quarter '25, compared to $10.6 million in the prior year period. The decrease in operating expenses was driven by a $0.6 million decrease in selling, general and administrative expenses, a $0.3 million decrease in research and development expenses, a $0.3 million decrease in salaries and related costs and a $0.2 million decrease in professional services expenses. We are pleased to see the results of the cost-cutting measures taken in the fourth quarter of '24 in our current numbers.
Loss from operations decreased $2.8 million or 77% to $0.8 million. Net loss attributable to stockholders was $2 million, or $0.05 per share for the third quarter '25, compared to $4.7 million, or $0.14 per share in the prior year period. Adjusted EBITDA loss decreased 96% to $0.1 million, compared to $2.4 million in the third quarter of '24. As a reminder, we provide a detailed reconciliation from net loss attributable to stockholders to non-GAAP adjusted EBITDA loss in our earnings press release.
For the 3 months ended September 30, 2025, cash used in operating activities decreased to $3.5 million, compared to $4.4 million used in the prior year period. For the 9 months ended September 30, 2025, cash used in operating activities decreased to $5.5 million, compared to $15.1 million used in the prior year period. We are pleased with the cash and working capital management in the first 9 months of 2025 with cash burn returning to a lower but more normalized rate in the back half of the year as a result of the impacting changes in working capital as a result of the AYON launch.
As of September 30, 2025, the company had cash and cash equivalents of $25.1 million, compared to $31.7 million as of December 31, 2024. We believe, based on our cash projections, including the uptake of the AYON platform, working capital management and our strict cost controls, we will yield cash through 2027.
Turning to a review of our '25 guidance, which we updated in our third quarter 2025 financial results press release issued earlier today. For the 12 months ending December 31, 2025, we expect total revenue in the range of $50.5 million to $52.5 million, up from our previous range of $50 million to $52 million. We believe this increase shows the strength of the AYON ongoing commercial launch, especially when you look back at our original guidance of $47.6 million to $49.5 million for '25 or compared to the $48.1 million for the year ended December 31, '24.
Our revenue guidance assumes Surgical Aesthetics segment revenue in the range of $43 million to $45 million, up from the previous guidance of $42 million to $44 million. Again, since we initiated the soft launch of AYON this summer, we have increased expectations for our original guidance of $39.1 million to $41 million. In addition, this is compared to the $38.6 million for the year ended December 31, 2024, reflecting current trends.
OEM revenue is expected to come in at approximately $7.5 million, down from the previous guidance of $8 million as the company focused resources on the Surgical Aesthetics segment, this is compared to the $9.5 million for the year ended December 31, 2024. For the purposes of clarity, we increased the guidance in the Surgical Aesthetics segment by $1 million and decreased the guidance in the OEM segment by $0.5 million from the guidance previously provided in our second quarter conference call. We now anticipate gross margins of approximately 61% for the year and total operating expenses not to exceed $40 million.
This completes our prepared remarks. Charlie and I will now open the call for questions. Operator?
[Operator Instructions] Your first question comes from Dave Turkaly with Citizens.
2. Question Answer
Congrats on the launch and the spending progress. I just had a clarification one upfront here. I know you said the generator sales were down, but I don't think I actually understood the explanation for why that wasn't. You said something about AYON, but I just want to clarify that upfront, if I could.
Yes. So look, we're changing, obviously, the way that we classify things because AYON obviously has to have an Apyx One generator. And if you think of our customer base, we have customers that already have an Apyx One generator, they can actually just buy the rest of AYON and have their existing Apyx One generator integrated into AYON. And then we have an installed base of RS3 generators. They need to upgrade to an Apyx One generator and then buy the rest of AYON. And then obviously, if they don't have any of our Renuvion technology, they would need to buy all of AYON that would include an Apyx One and an AYON with it. And so we're obviously classifying those as just AYON sales even though they have an Apyx One in them.
Got it. And then trying to think about the gross margin impact from this. I haven't -- I don't know that you publicly commented on sort of the ASPs or what the uptick might be here. But I guess I'm imagining that the handpiece and the capital might be premium to what you were selling in the past. And as we're looking forward, I don't know if you are comfortable giving any commentary, but I imagine there has to be a significant gross margin uptick if that is the case. And I don't know if you can give any color as we're all trying to look to the out years now, but how significant or how much of an uptick do you anticipate as this rollout continues?
Yes. No, thanks for the question, Dave, but you probably know what my answer is going to be in that we're not giving guidance out from either a revenue or a gross margin point of view. The only thing that I would say to that, just to give you a little bit of color is we've always said that the Surgical Aesthetics business, obviously, especially in the U.S., has the highest gross margins anywhere. So the more we sell here of that, the better it is for the entire company. But we're not going to give any color or any guidance on what that is right now.
The next question comes from Sam Eiber with BTIG.
So clearly, a really exciting opportunity on AYON and getting devices out in the market. But I want to ask maybe about on the consumable side and maybe some pull-through you can get on higher device utilization because of all the new capabilities that AYON has. So I guess my question is, should we also expect a big uptake in consumables in addition to capital sales next year?
So I think the uptake would come back from selling new units to people who don't have Renuvion technology today. I think for customers that are upgrading to Renuvion, they're using, obviously Renuvion after their liposuction procedures today. So I don't know that you would necessarily see an uptick from the existing base. But obviously, adding new customers will certainly help that. We had a good third quarter from a consumable standpoint, both in the United States and internationally. And obviously, we're always focused on driving utilization. So as we add more customers, that's going to be the greatest driver of utilization in the future.
Okay. That's helpful. Maybe I can ask a follow-up on the latest you're just seeing in the market environment. Just getting a sense of any changes to demand trends, GLP-1 dynamics at play? Would just your latest thoughts on the market at this point.
Yes. Look, I think it's consistent with what we've talked about before is we've always said that we believe the market has been disrupted from the GLP-1 drugs. We think that companies that have technologies that address skin laxity and address body contouring and are focused on the surgical side of things are going to be where the action is at. And we obviously think the technologies that we have with AYON and Renuvion are going to be very well suited to this marketplace as we keep moving forward and as more people are taking these drugs and having the side effects from these drugs and then wanting to have treatment from these.
I think the other side of it is it was McKinsey that just came out with the study that 63% of these patients that are on the GLP-1 drugs are new to aesthetics. And so I think we're just going to see -- I think we're in the early innings of this drug. And I think over the next decade, it's going to be a very good time to be a plastic surgeon in the world. That's for sure.
The next question comes from Alex Fuhrman with Lucid Capital Markets.
Congratulations on a really nice quarter and the launch of AYON. I wanted to ask you, Charlie, how much of your growth in the quarter was driven by the single-use handpieces? And what's really driving that? Are you seeing more lipo procedures being performed or better attach rates for Renuvion, or are you perhaps starting to see more stand-alone uses of Renuvion as well?
Yes. So I think the one thing that the quarter-by-quarter is always a tougher way to look at it. As you know, I think last quarter, we were down a bit. This quarter, we were really strong, both the United States and internationally in the growth of handpieces. And I think the answer to your question is all of the above.
So we're obviously seeing new doctors come in to adopt the technology for the first time. We're seeing a higher attach rate from patients that are coming into doctor's office and requesting Renuvion. And so after a body contouring procedure, they're going to use that. And then we are seeing it used on a stand-alone basis. And so I think the answer is all of the above for that.
And again, as people are looking for solutions to take care of their loose and lax skin, especially following the treatment of GLP-1s, I think this is a trend that's going to play out for a lot of years to come.
The next question comes from Matt Hewitt with Craig-Hallum.
Charlie, congratulations on the strong quarter. Maybe -- and I apologize if I missed this, but talking a little bit about the pipeline. So obviously, you've gotten the initial launch out. Customers have adopted and are utilizing the platform. You've done some KOL events. They're helping kind of spread the word. Are you seeing that pipeline not just grow, but maybe you're reaching an inflection point where it's accelerating faster? And if so, how are you able to kind of get those implementations done with the team? Have you had to add to that team to meet the demand or anything -- any color along those lines would be helpful.
Yes. Obviously, we increased our guidance by $1 million for Surgical Aesthetics in the fourth quarter. And so -- and you can see what that -- obviously, you can do the math and translate to see what that works out to in the fourth quarter from a revenue perspective. And obviously, that is on the back of AYON and our expectations for AYON.
As far as pipeline, I'm not going to comment too much about that, but the team has done an amazing job of get shoring up the supply chain, getting the supply chain to where it needs to be and being able to take advantage of the interest and the orders that we're getting with that we're getting with AYON.
As far as the installations go, we've got a third party that is helping us do that. And so that is taking away some of the burden from the existing employees. And -- but we're doing a really good job as a company of being able to make these to get them installed and to get the doctors trained and get their staff trained and get them up and running. And so it's been a very, very good rollout of a new product and especially a product with this much technicality and sophistication in it, and the team has just done an amazing job of that.
That's great. And maybe -- and I realize it's early days and you're focused on the U.S. market and rightfully so. But how should we be thinking about cadence of rolling AYON out internationally? Are there maybe 1 or 2 geographies that you'd like to target for '26? And remind us what that process is to bring AYON to the masses outside of the U.S.
Yes. No, it's a good question, Matt. And we're not going to get specific on that on today's call. But obviously, we want to have AYON registered everywhere in the world because it's not just a product for the United States. It's a product for every surgeon worldwide. Some of the bigger focus markets, obviously, would be Europe, the Middle East, Brazil, Latin America, some other countries in Latin America. Europe is all together. So Europe, you just need a CE mark. And once you get one, you get them all. There are some countries in the Middle East that actually accept FDA. And so obviously, those we would probably start sometime next year there.
And then each individual country has its own registration process, and we'll be starting those processes in a lot of the countries. So we'll talk more about that when we get into '26 and we start doing that. And you're right, our focus right now for the third quarter and the fourth quarter is solely on the United States.
At this point, there are no further questions. I will now turn the call over to Charlie Goodwin for closing remarks. Please go ahead, sir.
Thank you, everybody, for attending the call. I want to thank the entire Apyx team for their dedication and tireless execution over the past 3 months. It has been an exciting time for the company as we see our plan turn into reality. We appreciate all the support we've received from our shareholders during this time, and I thank you all for attending.
Thank you. Ladies and gentlemen, this concludes today's conference call. Thank you for your participation. You may now disconnect.
Financial data from Apyx Medical Corporation
Revenue
Revenue is the sum of all sales generated by a company, e.g. for its products or services.
Revenue (TTM) metric explainedDirect Costs
Direct costs are the costs incurred directly in connection with the manufacture of the product or service.
Gross Profit
Gross Profit indicates how much of the revenue remains in the company after deducting direct production costs. If the percentage share of sales is calculated, this is referred to as the gross margin.
Gross Profit metric explainedSelling and Administrative Expenses
Selling, general and administrative expenses (SG&A) include all expenses for marketing and sales as well as the general administration of the company.
Research and Development Expense
Research and development costs (R&D) provide information on how much the company invests in the research and development of its products. The costs are particularly interesting as a percentage of revenue and in comparison to direct competitors.
EBITDA
EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) is the company's earnings before interest, taxes, depreciation and amortization. The EBITDA margin is calculated as a percentage of sales.
Depreciation and Amortization
Depreciation represents reductions in the value of the company's assets (e.g. due to wear and tear on machinery).
EBIT (Operating Income)
EBIT (Earnings Before Interest and Taxes) is the company's profit before interest and taxes, also known as the operating income. The EBIT Margin is calculated as a percentage of sales at
.
Net Profit
Net Profit represents the profit or loss after deduction of all costs.
Net Profit metric explainedStocksGuide Premium
| Jun '26 |
+/-
%
|
||
| Revenue | 58 58 |
26%
26%
100%
|
|
| - Direct Costs | 21 21 |
19%
19%
36%
|
|
| Gross Profit | 37 37 |
29%
29%
63%
|
|
| - Selling and Administrative Expenses | 37 37 |
1%
1%
64%
|
|
| - Research and Development Expense | 3.30 3.30 |
15%
15%
6%
|
|
| EBITDA | -2.76 -2.76 |
77%
77%
-5%
|
|
| - Depreciation and Amortization | 0.78 0.78 |
39%
39%
1%
|
|
| EBIT (Operating Income) EBIT | -3.54 -3.54 |
71%
71%
-6%
|
|
| Net Profit | -8.63 -8.63 |
50%
50%
-15%
|
|
In millions USD.
Don't miss a Thing! We will send you all news about Apyx Medical Corporation directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Apyx Medical Corporation Stock News
Company Profile
Apyx Medical Corp. operates as an energy-based medical technology company. The firm engages in developing, manufacturing, and marketing a range of electrosurgical products and technologies, as well as related medical products used the offices of doctors, surgery centers, and hospitals worldwide. It operates through the following segments: Advanced Energy and Original Equipment Manufacture (OME). The company was founded by Andrew Makrides in 1978 and is headquartered in Clearwater, FL.
StocksGuide Premium
| Head office | United States |
| CEO | Mr. Goodwin |
| Employees | 205 |
| Founded | 1978 |
| Website | apyxmedical.com |


